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Associate Prof JonasWadströmandProfBo-GoranEriczon
This supplement reports on the proceedings of a meeting
titled “Advancing Transplantation: New Questions, New
Possibilities,” held at Karolinska Institutet in Stockholm,
Sweden, on January 24 to 26, 2015, and sponsored byAstellas
Pharma Europe Ltd. The meeting highlighted the challenges
facing the transplant community and the need to respond to
those challenges with new approaches, questions and possibil-
ities. Over 450 kidney and liver transplant professionals from
across Europe attended themeeting, which included talks from
keynote speakers, scientific presentations, panel discussions,
interactive sessions, and a poster session designed to allow
delegates to exhibit their own clinic's data.
Solid organ transplantation has evolved into one of the
great accomplishments in clinical medicine and remains the
only lifesaving treatment for many types of end-stage organ
failure. Breakthroughs in transplant procedures and the devel-
opment of effective immunosuppressive therapies have helped
health care professionals achieve significant improvements in
graft and patient survival posttransplant. This is evident across
all indications, including kidney and liver transplantation.1,2
Continuing the advances in improving long-term survival
remains a key challenge for transplant medicine today.2,3
Maintaining a transplanted graft over time is complex.
Multiple risk factors influence graft survival before, immedi-
ately after and late after transplantation. The use of marginal
donors, to reduce the disparity between demand and availabil-
ity of organs, has added to this complexity and brought new
challenges to the field of transplantation. Recent research in
the kidney and liver transplant arenas has identified a number
of risk factors that contribute to poor graft survival (Figure 1).
These risk factors can lead to irreversible pathological damage
to the transplanted organ, with a negative impact on patient
outcomes. By managing these risk factors, we aim to improve
the long-term survival of transplanted grafts for our patients.
Health care professionals need to continually reassess how
to improve care for their patients while managing limited re-
sources and embracing the new age of digital technology and
big data. Only by understanding the risk factors that are
modifiable and translating this into changes in the clinic
will the perspectives for patients be further improved. “Bestpractice” care for transplant patients needs to be constantly
updated, taking new clinical developments into consider-
ation. Here, we present our findings with regard to the ongo-
ing risk factors for poor long-term outcomes in kidney and
liver transplantation and our suggestions for best-practice
management for each of these risk factors. We also include
speculations as to future innovations that have the potential
to change patient management for the transplantation and
wider health care communities.• Improving long-term graft and patient survival remain
the key challenges for transplant medicine today; main-
taining a graft over time is complexwithmultiple risk fac-
tors that influence graft survival from organ procurement
to posttransplant follow up
• To improve graft and patient survival, both traditional
and emerging risk factors need to be identified and
modified, including nonadherence to treatment, high
variability of calcineurin inhibitor (CNI) exposure and
underimmunosuppression or overimmunosuppression
• Only by identifying these risk factors early and monitor-
ing for them routinely in clinical practice, will the patients
at risk of poor long-term outcomes be determined
• A number of risk factors for poor graft and patient sur-
vival can be modified by the choice of immunosuppres-
sive regimen usedPART 1: ONGOING CHALLENGES WITHIN KIDNEY
AND LIVER TRANSPLANTATION
Beyond Randomized Controlled Trials: Looking at
Data Differently
Dr Philip F Halloran
A key unmet need currently facing organ transplantation is
the requirement to improve transplant management in an
era where there are few new pharmaceutical company-
sponsored phase II and III clinical trials. To achieve this, it
will be necessary to optimize the use of new data sources to
understand outcomes, classify disease states, and confirm
FIGURE 1. Risk factors associated with poor graft survival in kidney and liver transplantation. *Fortunately, most liver transplant patients with
preformed DSA have uneventful resolution posttransplant; even liver patients with class II DSA with mean fluorescence intensity >10 000
[LABScreen single-antigen beads (One Lambda)] experience resolution two-thirds of the time.4 CNI, calcineurin inhibitor; DGF, delayed graft
function; DSA, donor-specific antibody.
© 2016 Wolters Kluwer Wadström et al S3associations in prospective, investigator-sponsored, observa-
tional trials at the individual patient level. This new under-
standing could lead to future tests, interventions, and clinical
trials, supported by the industrial investment that is needed
for optimal progress.
Randomized controlled trials (RCTs) have facilitated
many improvements in transplantation and continue to rep-
resent the standard we should strive to achieve. However,
as a data source, the RCT has some significant disadvan-
tages, particularly the inclusion of highly selective popula-
tions that may not adequately reflect the real world. These
populations are often excessively ‘front-end loaded’, being re-
cruited at the time of transplantation, with most events oc-
curring in the first few months posttransplantation, yet they
are being used to develop principles for long-term manage-
ment. To put this into perspective, most of the evidence from
trials has been based on events in the first year, yet 90%of or-
gan transplant patients are living beyond their first year
posttransplant. The protocols used can also affect the suit-
ability of the data, including the use of intent-to-treat designs,
limited study durations, and little human leukocyte antigen
(HLA) antibody phenotyping or recognition of antibody-
mediated rejection (AMR). RCTs are more likely to include
adherent patients, underrepresenting the serious problem of
nonadherence and difficulty in paying for the drugs long term.
Registries have several advantages over RCTs in that their
data sets are larger, all-inclusive, more diverse, and a better
representation of the real world, producing more generaliz-
able conclusions. Registry data, however, can also be heavily
influenced by inaccurate and incomplete data and con-
founders that lead to inappropriate conclusions. Registries
suffer from poor phenotyping, often permitting meaningless
categories, such as “chronic rejection.” Within these limita-
tions, registries remain important sources of data and should
not be underestimated. They are most useful for studying
unequivocal variables such as age and endpoints, such aspatient and graft survivals, and they have been useful in con-
firming the results of phase III trials. However, it is important
to distinguish between the trends that may be revealed by the
associations, and causality.
An example of the complexities of interpreting associa-
tions within registries can be seen in the association of donor
age and impaired graft survival. One of the driving factors of
the deceased donor-risk index is the age of the donor.5 For
example, as the age of the donor and the risk index increase,
there is a stepwise decrease in liver survival.5,6 The key ques-
tion is to understand the basis of this association and the phe-
notype and mechanism of the failures. Associations with
donor age are complicated by the inherent bias in organ allo-
cation. Because of clinician reluctance to give older organs to
low-risk young recipients, old organs are allocated preferen-
tially to high-risk older recipients, often with serious com-
orbidities that are difficult to capture in databases. This
strongly links the influence of old donor age and old recip-
ient risks, a bias that is not readily corrected by statistical
methods.7 In kidney transplantation, the relationship be-
tween recipient age and donor age is so strong that it is of-
ten impossible to ascribe a phenotype to either variable
alone.7 One result could be to overestimate the adverse
effects of donor age, triggering unnecessary organ discards.
The solution to this is to always try to translate risk factors
into phenotypes and mechanisms, and look for ways in
which an association may be misleading because of con-
founders. In other words, try to explain individual failures
in actual patients.
Improper analysis and incorrect validation have often oc-
curred in the application to transplantation of microarrays and
other “omics” technologies producing high-dimensionality
data, that is, manymeasurements per sample. Such data have
previously been criticized for “noise discovery,” particularly
in cancer research.8 However, a strict systematic approach
can harness these technologies and avoid such errors,9 and
S4 Transplantation ■ February 2017 ■ Volume 101 ■ Number 2S www.transplantjournal.comcan make microarrays and other molecular methods suitable
for diagnostic discovery and applications. Our strategy has
been to develop a reference set of biopsies and the patients
they represent, establishing the key parameters of the pheno-
type with maximum granularity and including clinical, labo-
ratory, histologic and molecular data. The errors in the
conventional classification should be corrected; the conven-
tional phenotype can then be used to “train” diagnostic tests
using the molecular measurements derived from the microar-
rays, assigning amolecular class to each biopsy by a diagnos-
tic equation (classifier) derived through machine learning,
usingmethods such as cross-validation to prevent overfitting.
The results should be validated in an independent biopsy set.
Once conventional classes have trained molecular tests, the
molecular tests can be used as standards to refine the conven-
tional classes, forming an iterative loop. It was this iterative
strategy that led us to realize that AMR was being greatly
underestimated by the requirement for C4d positivity; we es-
tablished the molecular phenotype then realized that the mo-
lecular changes of AMR were much more common than
C4d staining.10,11
Some of the older phase III clinical trials and registry data
analyses need to be reinterpreted as we learn about the limi-
tations of the diagnosis of rejection in earlier eras. This
is reflected in a recent study, which showed that T cell-
mediated rejection (TCMR) in indication biopsies does not
impact survival compared with the absence of rejection
within an indication biopsy population,12 contrasting with
the devastating effect of AMR in that population.12,13 The
limitation is that the best group to be in—those who never
have indications for biopsy—is not in the population studied.
Another study showed that v-lesions (intimal arteritis) are
now less common andmilder (usually v1), and have little effect
on prognosis except to the extent that they reflect AMR.14
Such analyses challenge the conventional wisdom of the signif-
icance of “rejection” and v-lesions in diagnosis and prognosis.
This illustrates the problem of “data drift”; that is, associa-
tions and risks change as practice changes. Conclusions
reached in earlier eras must be constantly reassessed for valid-
ity and relevance.
Analysis of “big data” from large administrative data-
bases and electronic health records has been used effectively
in some areas of medicine and may have applications in
transplantation, provided the same critical standards are
applied and confounders are sought. The predictions from
such studies must be validated in prospective studies,
and the mechanisms of the associations and the disease
phenotypes should be understood at the level of the
individual patients.
In conclusion, there are many opportunities beyond phase
III trials and much of the new insights will come from such
opportunities in the next decade. Research should start and
end with the struggle to understand and predict the events
in the individual patient, coupled with a questioning attitude
to the conclusions from earlier eras and a critical examina-
tion of the literature. Whether using registry data, high-
dimensionality data, or phase III trials, the project must be
approached with rigorous designs and validation, and must
search for mechanisms that explain associations. The goal
must always be to explain actual phenotypes and outcomes
in the clinic, and to use that information to change care. This,
in turn, will create opportunities for investment.Optimizing Immunosuppression: What are the Registries
Telling Us? The European Liver Transplant Registry
Prof Dr Wolf O Bechstein
Aswe enter an era in transplantationwhere there are fewer
ongoing large RCTs, we also rely on alternative methods of
data collection and analysis to answer clinical questions in
an attempt to further improve the long-term outcomes of
our patients. Not only do registries provide us with a large
amount of data that continues to expand over time, they also
provide long-term follow up beyond that of RCTs.
The European Liver Transplant Registry (ELTR) was in-
spired by the vision of Henri Bismuth, and was established
to create a database comprising the whole experience of
European liver transplant centers. Data are collected pro-
spectively using a standardized 2-part questionnaire,15 which
is regularly updated by a scientific committee. Part 1 com-
prises date and indication for the liver transplantation, donor
and recipient data, surgical technique used and immediate
postoperative immunosuppression therapy, and Part 2 com-
prises graft and patient outcomes and the longer-term immu-
nosuppressive regimen. The data held in the registry are
subject to strict internal and external quality control, with an-
nual audits of randomly selected centers.15 In 2003, an inde-
pendent audit of 21 centers found that 95% of the data held
in the ELTR was complete and the rate of consistency be-
tween the data held by the hospitals versus the ELTR was
98.5%.16 These findings indicate a high degree of accuracy
for the data held in the registry. To our knowledge, this is
the only transplant registry with regular random-sample ex-
ternal auditing. Data from the ELTR have provided valuable
insights in liver transplantation, including information re-
garding the use of organs from marginal donors,15 and the
development of a risk-analysis model to determine mortality
risk of a given procedure in an individual patient.17
Adam et al18 recently reported an analysis of data from the
ELTR comparing long-term graft and patient survival data
for all adult patients transplanted between January 2008
and December 2012 who received tacrolimus-based immu-
notherapy. The patient groups were stratified by the tacro-
limus formulation they received during the first month
posttransplant (prolonged-release vs immediate-release for-
mulation). For further analysis, patients remained in the orig-
inally assigned group even if the formulation was changed,
similar to an intent-to-treat analysis in RCTs. Data for the
patients with <1 month of follow-up were excluded. To pre-
vent center bias, only data from the 21 centers who had been
using both tacrolimus formulations were included.18 Data
for 4367 patients were analyzed (528 patients receiving
prolonged-release tacrolimus and 3839 patients receiving
immediate-release tacrolimus).18 In this study, the group of pa-
tients receiving prolonged-release tacrolimus demonstrated a
significantly higher rate of graft survival compared with the
group receiving immediate-release tacrolimus over 3 years of
treatment (88% vs 80%, respectively; P = 0.01). The numeric
difference of 8% between the treatment arms amounts to a
10% improvement in long-term graft function, or, in other
terms, a 40% risk reduction of graft loss.
The 3-year patient survival was 88% in the prolonged-
release versus 82% in the immediate-release tacrolimus
group (P = 0.07). The other risk factors reported included re-
cipient dialysis, higher United Network for Organ Sharing
(UNOS) status andmodel for end-stage liver disease (MELD)
FIGURE2. Kaplan–Meier analysis of graft survival over 3 years
of treatment with prolonged-release tacrolimus compared
with immediate-release tacrolimus after exclusion of patients with
<1 month of follow-up. Reprinted from Adam R, Karam V, Delvart
V, et al. Improved survival in liver transplant recipients receiving pro-
longed-release tacrolimus in the European Liver Transplant Registry.
Am J Transplant. 2015;15:1267–21282 doi:10.1111/ajt.13171.
© 2016 Wolters Kluwer Wadström et al S5score, serumcreatinine≥2mg/dL, total ischemia time≥12hours,
and hepatocellular carcinoma (HCC), hepatitis C virus
(HCV), and human immunodeficiency virus (HIV) status. In
the multivariate analysis, the 3 highest-ranking risk factors
for reduced graft and patient survival were found to be
HIV-positive serology (risk ratio: 3.40, 3.41, respectively), se-
rum creatinine concentration of ≥2 mg/dL (risk ratio: 1.84,
1.86, respectively), and treatment with immediate-release tacro-
limus immunotherapy versus prolonged-release tacrolimus (risk
ratio: 1.81, 1.72, respectively) (Table 1). Adam et al18 went on
to report 3-year Kaplan–Meier data showing an 8% graft sur-
vival advantage in the group receiving prolonged-release tacro-
limus versus those in the immediate-release tacrolimus group
(P = 0.01) (Figure 2) and a 6% (nonstatistically significant)
trend toward improved patient survival in the group re-
ceiving prolonged-release tacrolimus versus those in the
immediate-release tacrolimus group (P = 0.07). Longer-
term follow-up data for patients in the ELTR and an anal-
ysis of patients who switched between formulations after
month 1 are ongoing.
Adam et al18 carried out further analyses on a refined pop-
ulation to account for discrepancies in the baseline character-
istics between the 2 treatment groups using propensity score
matching (where patients were paired according to similar
predefined baseline characteristics, which had been identified
as significant risk factors in previously carried out univariate
andmultivariate risk analyses) on a 1:2 ratio (prolonged-release
tacrolimus:immediate-release tacrolimus). When the authors
analyzed data from these 810 patients (270 prolonged-release,
540 immediate-release tacrolimus) they confirmed a significant
graft survival advantage associated with the use of prolonged-
release versus immediate-release tacrolimus over 3 years in both
the univariate and Kaplan–Meier analyses. The patient survival
advantages also reached statistical significance. In the multivar-
iate analysis of the propensity score matched patient cohorts,
immediate-release tacrolimus immunotherapy was confirmed
as a risk factor for reduced graft and patient survival, second
only to ABO blood group incompatibility.
As we are beginning to understand more about the modifi-
able risk factors in transplantation, including nonadherence, var-
iability of tacrolimus exposure and underimmunosuppression,
this will help us to further understand the causes of the differ-
ences seen with prolonged-release compared with immediate-
release tacrolimus in terms of graft and patient survival.
In conclusion, these data show significant benefits in
survival postliver transplantation in patients receivingTABLE 1.
Multivariate analysis of risk factors for reduced graft survival afte
Risk factors at first transplant Ri
Recipient HIV-positive
Serum creatinine concentration ≥2 mg/dL
Immediate-release tacrolimus immunotherapy
UNOS status 1 or 2
Recipient anti-HCV positive
Total ischemia time ≥12 h during first liver transplant
Recipient age ≥50 y
HCC (primary or secondary disease)
Donor age ≥50 y
N = 3828. CI, confidence interval; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human improlonged-release versus immediate-release tacrolimus; how-
ever, a better understanding of the reasons for the differences
in survival is needed. This is an exciting era, but our knowl-
edgemust be transferred into clinical practice for these survival
advantages to be achieved in larger patient populations, and
we therefore need to redefine best practice for our patients. It
is important to establish how we can “operationalize” these
data to improve clinical practice.
Optimizing Immunosuppression: What are the Registries
Telling Us? The Collaborative Transplant Study
Prof Gerhard Opelz
The Collaborative Transplant Study (CTS) was initiated in
1982, and over the last 30 years, has collected awealth of data
on kidney, pancreas, heart, lung, and liver transplants that
have helped shape clinical practice. This registry was built on
a philosophy that the knowledge-gaining process can be accel-
erated by combining the experiences of many, especially with
respect to complex interactions of factors and the analysis of
rare events.19 In a therapy area where there are fewer RCTs,
and in an era of big data, the transplant community is beginning
to recognize the increasing importance of registry data to inform
decisionmaking that affects patient care and access tomedicine.
The CTS is a rigorous and strictly scientific registry based
on voluntary participation; over 20 000 new patient data setsr exclusion of patients with <1 month of follow-up
sk ratio 95% CI P
3.40 2.04-5.68 <0.0001
1.84 1.42-2.39 <0.0001
1.81 1.26-2.61 0.001
1.61 1.30-2.00 <0.0001
1.51 1.24-1.83 <0.0001
1.42 1.06-1.89 0.02
1.41 1.15-1.73 0.001
1.37 1.11-1.67 0.003
1.33 1.10-1.60 0.003
munodeficiency virus; UNOS, United Network for Organ Sharing. Table from Adam et al.18
FIGURE 4. Graft survival according to tacrolimus trough levels at
year 1 postkidney transplant. P value calculated using the log-rank
test for trough levels for all comparisons compared with the
<5.0 ng/mL group. (Collaborative Transplant Study, written commu-
nication, January 25, 2015).
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transplantation.1 Today, there are approximately 480 trans-
plant centers participating in the CTS: 292 specializing in
kidney transplantation, 87 in liver transplantation, and 101
in heart and lung transplantation. Although most of the cen-
ters originate in Europe, participation is worldwide and in-
cludes representation from South and North America, Asia,
and Africa. The last 30 years has seen improvements in
short-term and long-term survival rates across all trans-
plant fields, owing to significant advances in transplant
procedures and immunosuppressive therapies.
Clinical practice is continuously evolving with the addi-
tion of new data. Focusing on the kidney transplant setting,
in 1985, data from the CTS showed a significant improve-
ment in outcomes with cyclosporine A (CsA) compared with
existing immunosuppressive regimens.20 Over the next de-
cades, we reported that discontinuing steroid therapy was as-
sociated with improved long-term graft and patient survival
postkidney transplant, as well as a reduction in osteoporosis
and cataracts, and a trend toward reduced hypertension.21-23
Previously, data from the CTS registry also demonstrated a
link between maintenance steroid dose and death due to car-
diovascular disease or infection, although there was no asso-
ciation with death due to malignancies.1
From 2003 onward, there has been a dramatic shift in the
treatment paradigm, with the overwhelming majority of pa-
tients now receiving tacrolimus-based immunosuppression
rather than CsA. Consistent with previous reports, reduction
of maintenance steroid dose at 1 year was also shown to min-
imize the risk of cardiovascular-related and infection-related
deaths in patients receiving tacrolimus therapy. Data from the
CTS registry also supported results from other studies in dem-
onstrating that tacrolimusminimization 2 years posttransplant
is associatedwith an increased risk of graft loss.24One possible
explanation is that underimmunosuppression allows the T cell
response to return, increasing the production of donor-specific
antibodies (DSA) and leading to AMR.
Data from the CTS have shown a gradual, but significant,
decrease in median tacrolimus trough levels from 2003
onward (Figure 3).
This led us to question whether the decline in tacrolimus
trough levels observed has impacted graft survival. Analysis
of graft survival outcomes demonstrated that tacrolimus
trough levels less than 5 ng/mL at 1 year posttransplant were
significantly associated with inferior graft survival over
6 years (Figure 4). Although the causes of graft loss for allFIGURE 3. Median tacrolimus trough levels at 1 year postkidney
transplant from 2003 onward. P value calculated using the
Jonckheere trend test.patients are unknown, these data suggest that trough levels
less than 5 ng/mL might not provide sufficient immunosup-
pression postkidney transplantation (Collaborative Trans-
plant Study, written communication, January 25, 2015).
Evaluation of tacrolimus trough levels over time has
shown a rise in the proportion of patients with trough levels
less than 5 ng/mL (from 10% in 2003 to just under 20% in
2012), presumably in conjunction with a trend for tacroli-
mus minimization in clinical practice. Furthermore, in pa-
tients with tacrolimus trough levels less than 5 ng/mL at
1 year, the dose of mycophenolic acid (MPA) was found to
be a critical determinant for graft survival, with low doses
of MPA at 1 year (≤1 g/d) being associated with reduced
graft survival.25 However, it would be wrong to conclude
that increasing the dose of MPA provides sufficient immuno-
suppression in patients with low tacrolimus trough levels. In
fact, patients receiving higher dose MPA (with tacrolimus
trough levels <5 ng/mL at year 1), showed increases in tacro-
limus trough levels in subsequent years, presumably as a
result of clinical need.25 This underscores the importance of
targeting trough levels greater than 5 ng/mL, regardless of
MPA dose.
In patients with good graft function at 1 year, higher tacro-
limus trough levels were not associated with an increase in
new-onset diabetes after transplant (NODAT) or nephrotox-
icity (as evidenced by serum creatinine levels) at 5 years com-
pared with lower tacrolimus trough levels. Interestingly, in
patients with impaired graft function, a strong stepwise cor-
relation between graft function at 5 years and high tacroli-
mus trough levels was observed, indicating that raising
tacrolimus trough levels beyond 5 ng/mL improves graft
function in these patients.
Data in the CTS registry collected from patients treated
with the once-daily, prolonged-release formulation of tacroli-
mus are currently being analyzed. It will be interesting to
assess if the improvements in long-term graft and patient sur-
vival with prolonged-release versus immediate-release tacro-
limus that have been reported in liver transplantation18 are
also apparent in kidney transplantation.
In conclusion, the CTS registry provides a wealth of real-
world data that can inform clinical practice and improve
the outlook for kidney transplant patients. Where possible, re-
duction or withdrawal of corticosteroids should be considered
in patients receiving tacrolimus-based therapy to improve
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trough levels less than 5 ng/mL at 1 year is also associatedwith
inferior graft survival over the long term. As such, every care
should be made to maintain tacrolimus trough levels above
this threshold. Contrary to previous beliefs, higher tacrolimus
levels are not associated with NODAT and nephrotoxicity in
patients with good graft function. The observation that in-
creasing tacrolimus trough levels may improve graft function
in patients with impaired graft function is intriguing and war-
rants further investigation.
As the importance of these types of observational studies
becomes increasingly evident, there is an ongoing shift in
attitude to see the value of registry data in informing critical
decision making. Moving forward, even with the challenges
outlined in the previous section, registry data are set to sup-
port data generated via RCTs and impact patient manage-
ment, therapies, research and innovation.
The Kidney Graft Journey and Risk Management
Prof Daniel Serón
The insidious accumulation of risk over time can lead to
poor long-term outcomes; we know that the interrelation-
ships between risk factors for graft survival, due to the com-
plexity of the transplanted graft, are complicated. However,
some of these risk factors can bemodified bymaking changes
to our patient management and clearly defining the best prac-
tice of care.
It is important to evaluate and reevaluate the risk factors
for poor graft survival as clinical practice changes. Over the
last few decades, knowledge, attitudes, pharmacological inter-
ventions, concerns about cardiovascular disease, and other
factors, have evolved. A Spanish epidemiology study showed
that late renal allograft failure is a changing scenario due
to changes in patient management. For example, between
1990 and 1998 there was a decline in rejection but an
increase in cytomegalovirus infection.26 The risk factors over
time for an individual patient also change; those at 5-year and
10-year posttransplant have different challenges when com-
pared with those at 1 year.
Even our understanding of the effect of risk factors on
long-term outcomes at 1 year posttransplant has changed.
Ten to 15 years ago, there was a belief that CsAminimization
improved and preserved renal function; however, progression
of interstitial fibrosis assessed by biopsies at month 4 and year
1 posttransplant were associated with underexposure of im-
munosuppression.27 In general, tacrolimus-treated patients
have been shown to have a better graft survival rate ver-
sus CsA.28 Furthermore, tacrolimus minimization and with-
drawal strategies have been associated with a decline in graft
survival compared with tacrolimus continuation.29 Our un-
derstanding now is that to target tacrolimus trough levels
too low constitutes a significant risk for poor outcomes. High
variability of tacrolimus exposure is also considered to be a
modifiable risk factor for kidney transplant recipients and
has been associated with an increased risk of rejection and
poor graft survival.30,31
Another modification of our beliefs has been the assess-
ment of patients who are nonadherent to treatment, and this
is continuing to evolve. Fifteen years ago, we believed that
most transplant recipients were adherent. In Europe particu-
larly, this seemed logical because the European health sys-
tems fund immunosuppressive drugs, meaning that cost isnot a barrier to adherence in these patients. However, we
now understand that nonadherence is a significant concern
in transplantation and data from the United States Renal
Data System have confirmed that it is, indeed, a risk factor
for poor graft survival.32
In order to improve outcomes for our patients, the initial
conditions of the transplanted graft need to be assessed, as
these have an impact on its long-term survival. Nankivell
et al33 demonstrated that subclinical inflammation post-
transplant is a risk factor for progression of chronic inter-
stitial damage. Interstitial fibrosis/tubular atrophy and
inflammation together in the same biopsy have also been
shown to have an elevated risk effect for poorer long-term
outcomes,34 whereas in another study, inflammation de-
tected in 1-month and 4-month biopsies has been associated
with progression of fibrosis at 1 year.35
More recently, it has been shown that inflammation
early posttransplant is associated with the development of
de novo DSA in patients who are nonadherent to treat-
ment.36 There is also a correlation between high levels of
inflammation in the interstitium and elevated donor-
specific immune response.37 Another important modifiable
risk factor that occurs early in the graft journey is ischemic
reperfusion injury (IRI), which can inflict irreversible dam-
age to the kidney. The inflammation associated with IRI
may play a role in the cardiovascular risks associated
with transplantation.
Interestingly, these risk factors can be modified by the im-
munosuppressive regimens used, for example, everolimus
has been associated with a higher incidence of DSA versus
CsA,38 while tacrolimus-based regimens are associated with
less inflammation compared with CsA-based regimens.39
With tacrolimus immunosuppression in mind, it seems a fair
assumption that good adherence to treatment, low variabil-
ity and adequate exposure play a role in reducing inflamma-
tion, DSA and, subsequently, AMR early posttransplant.
Moreso et al39 demonstrated that baseline immunosuppres-
sion not only influences the incidence of clinical acute rejec-
tion (AR), it also influences the degree of inflammation in
early protocol biopsies. Once we diagnose “full-blown”
AMR, our options to modify its natural history and the graft
journey are very low; we need to act early, as the decisions
we make early posttransplant impact long-term outcomes.
Even the risk factors that may not translate to changes in cre-
atinine and proteinuria have important consequences 5 to
10 years posttransplant.
Improving long-term outcomes remains a common goal
in transplantation, and we know that immunologic and
nonimmunologic risk factors have an impact on graft sur-
vival. We need to concentrate our efforts on modifying
the risk factors that may improve survival early post-
transplant. The therapy that we choose for our patients is
a variable that can be modified and there is probably still
room to better use these immunosuppressive treatments.
More research is needed in both a randomized-controlled
setting and in a real-world environment to determine the op-
timal immunosuppressive regimens for each patient group.
The following sections in this paper further discuss a num-
ber of modifiable risk factors, including the development
of DSAs, underimmunosuppression, nonadherence to treat-
ment, IRI, delayed graft function (DGF) and cardiovascular
complications.
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Kidney Transplantation
Prof Josep Grinyó
Although IRI is considered to be unavoidable in solid or-
gan transplantation, there are a number of new diagnostic
and therapeutic approaches that could help to improve
long-term graft outcomes. Organ preservation and manage-
ment needs to begin at the source; by managing our donors
in a better way, improving organ preservation after retrieval
and attenuating reperfusion, we can aim to prolong the life
of the transplanted graft.
The UNOS previously recommended a variety of pre-
defined donor management goals to optimize the hemo-
dynamic stability of the transplanted graft.40 Where these
strategies have been implemented in clinical practice the risk
of DGF in kidney transplantation has been reduced by ap-
proximately 50%.40
Nowadays, we have to deal with a population of donors
with organs that may be more susceptible to IRI; we are an
aging society with older recipients and donors. It would be
expected that patients who receive organs from expanded-
criteria donors (ECDs) would have higher rates of DGF,
poorer renal function and reduced graft survival, as they
may be more vulnerable to the inflammation generated dur-
ing IRI. These organs, which potentially have preexisting le-
sions, could also have an impaired capacity for regeneration
after IRI.
Data from the Organ Procurement and Transplantation
Network/Scientific Registry of Transplant Recipients support
these observations and show that the incidence of DGF is de-
pendent on donor characteristics. For the ECDswho donated
after cardiac death, there was an over 50% increase in DGF
compared with the standard-criteria donors (SCDs).41 Simi-
larly, Moers et al42 reported a higher odds ratio of DGF for
ECDs versus SCDs. ECDs were also associated with a higher
risk of graft failure within the first year posttransplant.
There is a gap in the literature between experimental re-
search addressing IRI and clinical data that can be translated
to clinical practice, although there is ongoing research into
modifying risk factors associated with IRI.43 A US registry
analysis demonstrated that machine perfusion reduces the
risk of DGF and 1-year graft failure by approximately 50%
versus cold storage42; however, there was no significant dif-
ference in the magnitude of the treatment effect on DGF with
SCDs versus ECDs.42 A meta-analysis demonstrated similar
results,44whereas in a separate study, graft survival remained sig-
nificantly higher in the machine perfusion group at year 3.45
Kwiatkowski et al46 reported a significant improvement in
both graft survival and renal function at 5 years. In a separate
study, DGF and cold ischemia time more than 24 hours were
associated with a reduction in graft survival; however,
patients with DGF but without AR did not experience an in-
ferior graft survival rate.47 Different thermic regional perfu-
sion techniques show promise; when studied in organs
donated after circulatory death, normothermic regional per-
fusion, in particular, has considerable potential to restore
the quality of these grafts.43 Oniscu et al48 also demonstrated
a low occurrence of DGF (40%) when normothermic re-
gional perfusion was used. When looking at clinical practice,
we see that machine reperfusion is being used, especially in
centers that have ongoing ECD programs. To complement
these efforts, there is a Consortium for Organ Preservationin Europe that has been formed to conduct several random-
ized trials on different techniques for the preservation of kid-
ney and liver transplants. We eagerly await these results.
Donor management strategies should be used within the
context of patient management and alongside pharmaco-
logical therapies in an attempt to improve patient outcomes.
Taking into account the many different pathways and
mechanics involved in IRI, by using multitargeted therapy
(as we do in the case of the prevention of AR), we could fur-
ther improve long-term outcomes.
Perhaps the most effective tool that we have available in
our clinics today for the preservation of kidney transplants
is to assess the risk of developing DGF. Irish et al49 reported
a score index that has now been adopted in a number of
phase II trials to predict the high-risk patients who would
benefit from selective interventions. These assessments of risk
for DGF could be a useful tool in clinical practice to select
those patients that may benefit most from the new techniques
and pharmaceutical interventions. By identifying at “risk”
patients and modifying the risk factors for poor graft sur-
vival, we may achieve better outcomes for our patients in
the long term.
DSA-Mediated Allograft Injury in Kidney
Transplantation: New Understandings
Dr Alexandre Loupy
Over the years, DSAs have become a major challenge in
solid organ transplantation and are now the cornerstone of
allograft injury in many areas, including renal, heart, pancre-
atic, liver, and lung transplantation. Because AMR is the
leading cause of kidney allograft loss,50 focusing on improv-
ing adherence to immunosuppressive regimens and ensuring
adequate exposure to tacrolimus is essential to avoid the for-
mation of de novo DSAs and graft failure.
Advances in assays and screening techniques have helped
to highlight the emergence of DSAs and enabled a better un-
derstanding of their contribution to events such as AMR. Re-
cent studies have focused on the subclinical AMR outcomes
and highlight the necessity of improving the therapeutic man-
agement of our patients. In an observational prospective
study of 1307 kidney allograft recipients transplanted in
Paris between 2000 and 2010, subclinical AMR at 1 year
was one of the main independent determinants of long-term
kidney allograft loss, independent of conventional assess-
ments.13 The patients were divided into 3 groups based on
their phenotype at 1 year posttransplant: those with no rejec-
tion (n = 727), those with subclinical TCMR (n = 132) and
those with subclinical AMR (n = 142). Patients with subclin-
ical AMR at 1 year had worse kidney allograft function at
8 years compared with the patients in the subclinical TCMR
and nonrejection groups (Figure 5).13 Additionally, at year 8
posttransplant, patients in the subclinical AMR group had the
poorest graft survival (56%) compared with the subclinical
TCMR (88%) and nonrejection (90%) groups (P < 0.001).13
Subclinical AMR at 1 year posttransplant was evaluated in a
multivariate Cox model and was independently associated
with a 3.5-fold increase in long-term allograft loss (95% con-
fidence interval (CI): 2.1-5.7), together with proteinuria and a
low or intermediate estimated glomerular filtration rate
(eGFR) (P < 0.001).13 These data accentuate the growing
concern regarding indolent AMR phenotypes on long-term
outcomes. Other studies reinforcing this concern show that,
FIGURE 5. Long-term kidney allograft function according to a 1-year
subclinical rejection profile. The evolution of eGFR (MDRD) in 1001
patients on the basis of assessment of 4 511 longitudinal eGFRs is
shown. The long-term course of eGFR in 3 groups of patients was
evaluated using a linear mixed model starting from 1-year post-
transplant to the last available eGFR; 905 eGFR measurements taken
at 3 months posttransplant are also shown. Bars represent SDs.
AMR, antibody-mediated rejection; eGFR, estimated glomerular filtra-
tion rate; MDRD, modification of diet in renal disease; SD, standard
deviation; TCMR, Tcell-mediated rejection. Adapted with permis-
sion of The Journal of the American Society of Nephrology from
Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes
at 1 year post-transplant and outcome of kidney allografts. J AmSoc
Nephrol. 2015;26:1721–1731. Adaptations are themselves works
protected by copyright. So in order to publish this adaptation, authoriza-
tionmust be obtained both from the owner of the copyright in the original
work and from the owner of copyright in the translation or adaptation.
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component C5 antibody treatment, eculizumab, could not
reduce the subclinical forms of AMR.51 These recent results
have reshaped our understanding of AMR, defining it as a
continuous process with varying levels of injury and stages
rather than a discrete event.
Recently, a number of studies using contemporary tools
have increased the knowledge of the pathogenesis of DSAs.
In particular, a population-based study of 1016 carefully
phenotyped kidney transplant recipients from 2 French cen-
ters demonstrated that the complement-binding capacity of
DSAs play an important role in kidney allograft failure. Pa-
tients with complement-binding DSAs posttransplant had a
worse allograft survival rate at 5 years (54%) compared with
those with non-complement-binding DSAs (93%) and pa-
tients without DSAs (94%; P < 0.001 for both comparisons).
This study emphasized that the addition of the complement-
binding capacity of DSAs to conventional risk factor models
should be used to identify patients at high risk for kidney-
allograft loss.52 Further results of an independent analysis ex-
amined the impact of immunoglobulin G (IgG) subclasses on
injury patterns and suggested that subclinical AMR is typi-
cally driven by IgG4, whereas acute clinical AMR is mainly
driven by IgG3.53
In an attempt to address the limitations of conventional his-
tologic assessment, molecular microscope biopsy measure-
ments, using a microarray-based molecular microscope, have
added to the armamentarium for the assessment of transplant
biopsies.54Molecularmicroscopywas used in addition to con-
ventional clinical, histologic and immunologic features to eval-
uate the potential impact of this approach in terms of
prediction of the risk of graft loss and disease progression.
Adjusting for conventional features, AMR molecular score(hazard ratio, 2.22; 95% CI, 1.37 to 3.58; P = 0.001) and en-
dothelial donor-specific antibody-selective transcripts (hazard
ratio, 3.02; 95%CI, 1.00 to 9.16;P<0.05)were independently
associated with an increased risk of graft loss. Moreover,
adding this gene expression assessment to a traditional risk
model improved the stratification of patients at risk for graft
failure.55 Molecular microscopes might also help physicians
to assess the response to rejection treatment and may help to
adjust the immunosuppressive therapy.
Our new understanding of the nature and pathogenesis of
DSAs and how they relate to kidney biology will inevitably
lead to changes and improvements in treatment approaches
for kidney transplant patients. One suggestion would be to
improve therapeutic outcomes by focusing on AMR preven-
tion rather than treatment after its appearance.56 However,
to achieve this, effective screening procedures and improved
kidney allocation policies must be in place. Other suggestions
to improve treatment outcomes include avoidance of trans-
plantation in patients with preexisting DSAs, screening and
active management of nonadherence to immunosuppressive
treatment, and reinforcement of adequate exposure to tacro-
limus both early posttransplant and over the long term. By
modifying these risk factors with the immunosuppressive reg-
imens administrated to our patients we aim to reduce the oc-
currence of DSAs and improve patients' outcomes. Given the
involvement of distinct subclasses ofDSAs in kidney allograft
injury, these characteristics should also be taken into account
beyond simply testing patients positive for DSAs; an unmet
need is to recognize that the population of preformed and re-
current DSAs is different from the de novo DSA population.
As we move toward a more personalized approach to kid-
ney transplantation and redefine what “best practice” treat-
ment looks like, our ability to integrate all available and
multidimensional data, including phenotypic, histopatho-
logic, transcriptomic and immunologic information, will
prove critical to identify appropriate treatment approaches
for different patients.Nonadherence toTreatment inKidneyTransplant Recipients
Prof Christophe Mariat
Nonadherence to immunosuppressive treatment in kid-
ney transplant recipients is well established as a risk factor
for poorer long-term outcomes; however, identification of
nonadherent patients before the onset of clinical conse-
quences can be difficult.57-59 In 2009, The American Society
of Transplantation defined nonadherence as a deviation from
the prescribed medication regimen that is sufficient to ad-
versely influence the regimen’s intended effect.60Many factors
have been associated with nonadherence in the literature and
some of those factors, such as age, social factors, education,
type of employment, history of nonadherence with a previous
transplant, and history of addiction, are related to patient char-
acteristics.Other factors include those that are directly related to
the treatment: the taste and the size of the pill, anticipated or
experienced adverse events, and the complexity of the drug
regimen.61 Siegal and Greenstein classified 3 different types
of nonadherence profiles based on patient behavior/belief.62
1. Accidental: patients who forget to take their medication
(47% of nonadherent patients fall into this category)
FIGURE 6. Distribution of the attributed causes of graft failure in the
biopsy-for-cause population. Failures that could not be attributed,
owing to missing clinical information, are not represented (n = 4).
AMR, antibody-mediated rejection. Reprinted with permission from
Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes
of kidney transplant failure: the dominant role of antibody-mediated
rejection and nonadherence. Am J Transplant. 2012;12:388–399.
S10 Transplantation ■ February 2017 ■ Volume 101 ■ Number 2S www.transplantjournal.com2. Invulnerable: patients who feel that they do not need to take
their medication (28%)
3. Decisive: patients who actively decide not to take their med-
ication based on an observed or scientific rationale (25%)
Before an assessment of the prevalence of nonadherence in
transplantation is attempted, it is very important to stress the
difficulty of accurately measuring adherence to treatment.
The “gold standard” would be to actually witness the drug
being taken by the patient, but obviously it is very difficult
to implement this method in practice. Therefore, it is neces-
sary to become familiar with drug-monitoring systems. Indi-
rect methods of measuring adherence to treatment include
pill counts, pharmacists' refill records, self and collateral re-
ports, and interviews. Electronic monitoring devices are usu-
ally considered the “reference” for measuring nonadherence
in clinical research, although no actual recognized gold stan-
dard currently exists. For this reason, tomake an accurate as-
sessment of the prevalence of nonadherence in our patients, it
is necessary to combine different methods of data collection.
Schäfer-Keller et al59 reported a 12% to 39% nonadher-
ence rate in the population of kidney transplant recipients
studied, demonstrating that the prevalence of nonadher-
ence was dependent on the measurement used. None of the
methods they used in their study are considered good inde-
pendent diagnostic measures of adherence. The highest spec-
ificity was achieved by the interview technique, but only
when the interview had been conducted by 3 or more differ-
ent physicians, and the highest sensitivity was achieved with
the composite score. These data indicate that a well-defined
composite score for nonadherence could be a beneficial tool
in clinical practice. Not surprisingly, therefore, the incidence
of nonadherence in kidney transplantation reported in the lit-
erature is variable. In a study by Dharancy et al,63 the preva-
lence of nonadherence measured by physician assessment
was reported as 47% for kidney transplant patients versus
49% for liver transplant patients. When nonadherence was
reported using a patient self-assessment method, there was
a significant difference in the incidence reported. In 61.6%
of cases, physicians considered their patients to be adherent
to treatment, whereas the patients considered themselves to
be only moderately or poorly adherent.
Nonadherence to treatment has been shown to increase
over time and different types of nonadherence can have dif-
ferent impacts on clinical outcomes. In a French cohort,
35% of patients were nonadherent to treatment by year 2
posttransplant.64 When the nature of the nonadherence was
assessed, it was thought to be partially as a result of not tak-
ing the medication at the appropriate time, which may not be
as dangerous as not taking the medication at all.
The clinical consequences of nonadherence to treatment
are widely documented in the literature, and there is emerging
evidence to suggest that nonadherence is a risk factor for late
AR and graft loss.57,58 In 2012, Sellarés et al57 outlined what
is now considered to be the natural history of graft failure,
highlighting that there is a direct link between the develop-
ment of DSAs, nonadherence to treatment and graft loss. Of
the patients in this study who experienced graft failure, 47%
were considered to be nonadherent to treatment (Figure 6).
To summarize, nonadherence to treatment in transplanta-
tion is well defined; however, the occurrence and type of non-
adherence is not easy to capture, and there is a need to usedifferent methods of diagnosis to get an overall picture that
is truly reflective of solid organ transplantation. A number of
new technologies aiming to address the issue of nonadherence
are available, including interactive voice response systems,
ingestible sensors and smartphone apps. Nonadherence is as-
sociated with high clinical and financial burden, rejection,
graft loss, return to dialysis, and retransplantation. We should
systematically and longitudinally assess all our patients' adher-
ence to their medication, not only those who are presumed to
be at high risk of being nonadherent. Taking this approach to
managing nonadherence and introducing innovative technolo-
gies to support patients to modify their behavior will make
steps towards improved outcomes over the long term.
Prof Dirk Kuypers
To improve our patients’ outcomes we must manage non-
adherence to treatment; however, this management, in any
therapeutic setting, has to be accompanied by techniques to
identify nonadherence in the patient population. Two system-
atic reviews on nonadherence to treatment, encompassing
approximately 37 studies, assessed interventions in different
therapeutic areas. For patients who received education alone,
the improvement in adherence was small. When a behavioral
intervention was implemented (reduction in the burden of
tablets), then the effect size was larger. When both strategies
were implemented together, the magnitude of the effect was
further increased; this was dependent on how many times
the patients were reeducated about the risks of nonadherence
to treatment.65,66
In transplantation, there are also 2 strategies to manage
nonadherence; either the implementation of educational
patient programs or simplifying the dosing regimen of the
medication. When prolonged-release tacrolimus (Advagraf,
tacrolimus prolonged-release hard capsules) came to themar-
ket, we decided to determine if using a simplified regimen
with this drug really improved adherence to treatment. The
ADMIRAD study (ADherence Measurement In stable Renal
transplant patients following conversion fromPrograf (tacro-
limus hard capsules) to ADvagraf ) assessed adherence to the
immediate-release tacrolimus formulation for 3months, then
patientswere randomized to continue treatment or to convert
(1:2 ratio) to the prolonged-release formulation and moni-
tored for a further 6 months. Adherence was measured by a
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the used blister package is inserted into the electronic device
after taking a tablet and the date and time is registered. Interest-
ingly, in this study, patients were less adherent to the afternoon
versusmorning dose of immediate-release tacrolimus.67 Thiswas
thought to be related to less stringent routines in the afternoon.
For the implementation indicator, that is, percentage ofmed-
ication taken, on a day-to-day basis, a significant improvement
in adherence of 10%was achieved with prolonged-release ver-
sus immediate-release tacrolimus (Figure 7).67 When the time
of administration was included in the analyses, to give a more
stringent assessment of adherence (±2 hours), a significant dif-
ference of 10% was still observed. However, the 10% differ-
ence between the 2 groups was not statistically significant
when persistencewasmeasured, that is, patients who remained
on the prescribed dosing scheme.67
The Helping Hand device was able to detect different pat-
terns of nonadherence in our patients. We observed patients
who were occasionally nonadherent to their treatment, those
who took their doses later than prescribed during the week-
ends, those who were more likely to miss the evening versus
the morning dose of immediate-release tacrolimus and those
who became increasingly nonadherent over time.67
TheMedication Adherence Enhancing Strategies in Trans-
plantation study group are conducting a study in solid organ
transplantation (heart, liver, lung), examining adherence in
patients on a twice-daily tacrolimus-based regimenwhowere
randomized to one of 2 arms: Arm 1 included patients who
received an educational refreshment course, feedback on the
printout of their Helping Hand devices, motivational inter-
views, reminder systems and training in problem-solving skills;
Arm2 included patientswhowere given the readouts from their
Helping Hand device at each study visit. This study is useful as
it assessed the combined effect of motivational and educational
support. These kind of new study initiatives have encouraged us
to expand our trials to look at patient lifestyle and general health
issues in an attempt to further improve adherence to treatment.
With this in mind, we are in the process of setting up a new
study in our clinic. After interviewing a sample of our pa-
tients we have decided not to use a smartphone app for the
trial, as only a minority have suitable devices. Our patients
also told us that entering data into a computer each dayFIGURE 7. Implementation of dosing regimenwith prolonged-release
versus immediate-release tacrolimus. Correct dosing is defined when
the medication intake that day is at least as prescribed. Dashed line
at Time 0 represents time of randomization. The overlaying lines are
model-based estimations of the day-to-day percentages. Reprinted
with permission from Kuypers DR, Peeters PC, Sennesael JJ, et al.
Improved adherence to tacrolimus once-daily formulation in renal re-
cipients: a randomized controlled trial using electronic monitoring.
Transplantation. 2013;95: 333–340.would be a barrier to the trial, as it would interfere too much
with their regular daily routine. Therefore, we are taking a
new approach; we have provided a platform where the pa-
tient does not have to input their own data. Adherence to
treatment will be measured by a pill bottle that is electroni-
cally monitored, and physical activity and weight will be
monitored by a step meter and scales, respectively, which au-
tomatically record the information.We expect to have results
from the Picasso-Tx Study (is there a Preference for InteraCtive
Health Technology Applications to support Self-management
in Solid Organ transplant (Tx) recipients?) in 1 to 2 years.68
Finally, I want to discuss how you can intervene in a clini-
cal setting to improve patient adherence to treatment. This is
a proposition that we have, at least in part, implemented in
our hospital. During pretransplant consultations, patients
have the opportunity to discuss their care and the importance
of adherence to treatment with a multidisciplinary team,
including transplant nurses/nurse specialists, the attending
physician, the transplant coordinator, a dietician and psy-
chologist(s), and so on. On day 5 posttransplant, we conduct
routine monitoring and initiate an educational program with
the patients. At month 3, when we take a protocol biopsy, we
implement an educational refresher course and a question
and answer session about lifestyle, medication intake, side ef-
fects, diet, and a number of other factors with the responsible
nurse. Variability of tacrolimus exposure is also a potential
flag for nonadherence, and this is discussed with the patient.
At month 12, we repeat the interventions if a patient has re-
quested information involving their medication regimen or
lifestyle. Perhaps implementing this type of program over a
longer period would be beneficial in improving medication
adherence and, subsequently, long-term outcomes. However,
we would need to consider the technology and practicalities
that can be used for these interventions in clinical practice.
In addition to the technologies already discussed, dry blood
spot monitoring to allow tacrolimus trough levels to be mea-
sured at home, nonadherence questionnaires, such as the Basel
Assessment of Adherence with Immunosuppressive Medica-
tion Scale (BAASIS) questionnaire, and different smartphone
apps, like the risk factor calculator (Astellas Pharma Europe
Ltd, UK), could be of assistance.
In conclusion, nonadherence to treatment in transplanta-
tion is more frequent than we initially suspected and can be
determined andmonitored using a combination of instrumental
tools and targeted questioning of patients. Nonadherence to
treatment is a risk factor for poorer outcomes in solid organ
transplantation, including late AR, the development of DSAs,
chronic graft injury and graft loss.57 Treating nonadherence in
clinical practice is actionable and manageable and can make
a significant difference to the long-term outcomes of our pa-
tients.67 Reducing the pill burden and implementing/repeating
educational and support programs have the potential to achieve
significant and long-lasting improvements for the outcomes of
our patients, and we eagerly await data from ongoing studies
in our clinic.
Variability of Immunosuppressive Exposure in
Kidney Transplantation
MrMarc Clancy
Historically, reducing the incidence of AR has been the
main focus in clinical practice. However, new advances in
immunosuppressive regimens have led to a shift in focus
FIGURE 8. Potential link between variability of tacrolimus exposure
and de novo DSA in kidney transplantation (M. Clancy, written com-
munication, January 25, 2015). DSA, donor-specific antibody; dnDSA,
de novo donor-specific antibody; IgG, immunoglobulin G; MFI, mean
fluorescence intensity; Tx, transplant.
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study provided evidence for improved 1-year outcomes with
tacrolimus plus mycophenolate mofetil (MMF) and cortico-
steroids compared with the other regimens studied.69 This
regimen has been applied in an unselected “real world” pop-
ulation of patients in our unit, and has provided benefits in
terms of reducing rejection and graft failure, and improving
renal function in the first year posttransplant.70 However,
longer-term success requires modification of the key risk fac-
tors associated with poor graft and patient survival. Many of
these are generic to all individuals, such as diet and lifestyle,
but the key modifiable factor for a transplant patient is opti-
mization of maintenance immunosuppression.
Because tacrolimus is a narrow therapeutic index drug, small
variations in systemic exposure can lead to large differences in
the pharmacodynamic response. Overimmunosuppression is
associated with an increased incidence of infectious, toxic and
malignant adverse events, while underimmunosuppression
can lead to a breakthrough of the alloimmune response mani-
festing as AR, AMR, and/or the emergence of de novo DSA.
Immunosuppression exposure is usually measured via the
surrogate, trough tacrolimus level. Variability of tacrolimus
exposure occurs both between individuals, and within the
same individual at different time points. For this reason, both
interpatient and intrapatient variabilities must be taken into
consideration when managing patients in clinical practice.
Many of the factors associated with interpatient variability
(sex, CYP3A5 polymorphisms, and so on) are constant and
their effects occur early, allowing active clinical management
to resolve any potential problems. In contrast, the modifiable
risk factors that affect intrapatient variability are ongoing
and relate, in part, to adherence behaviors: taking the drug
at the right time with the right stomach conditions (food/no
food) and other lifestyle factors that affect trough levels,
as well as the practical factors associated with measuring
trough levels.
Intrapatient variability of tacrolimus exposure is typically
measured by the percentage deviation from the mean level
of all trough levels within a given time period or by the coef-
ficient of variation of the same set of levels. It is widely ac-
cepted that graft and patient survival can be affected by
large falls or rises in tacrolimus trough levels, well outside
the target range; however, the clinical impact on the patient
of small fluctuations outside the therapeutic range also ap-
pears to be important. As early as 2000, Kahan et al71 dem-
onstrated that patients in a higher-variability cyclosporine
cohort exhibited a higher incidence of graft loss compared
with patients in the lower-variability cohort. Similar findings
regarding the impact of cyclosporine variability on long-term
outcomes were also reported by Waiser et al.72 In a study of
46 pediatric transplant recipients, higher variability of tacro-
limus exposure was associated with the presence of acute re-
jection,30 and Borra et al31 reported a significant relationship
between high within-patient variability of tacrolimus expo-
sure and long-term graft failure. Furthermore, in a recent
study of 220 kidney transplant recipients, higher tacrolimus
intrapatient variability predicted accelerated progression of
chronic histologic lesions before onset of renal dysfunction.73
The lower-dose tacrolimus plusMMF and steroid regimen
used in the Symphony study is the most commonly used in
clinical practice. In a subanalysis of data from this study,
intrapatient variability of tacrolimus exposure of ~28%was apparent with this regimen in the first 12 months. Of in-
terest is that only 11% of patients had trough levels that were
within the target range at all times during the first 2 months
posttransplant.74 Armed with the information that a higher
variability of tacrolimus exposure leads to poorer long-term
outcomes,31 best practice should now be to recognize high
variability of tacrolimus exposure as a risk factor for poor
long-term outcomes, and to modify this risk factor in clinical
practice. By making changes to the immunosuppressive re-
gimen and reducing the variability of tacrolimus exposure,
further improvements in long-term outcomes for kidney
transplant recipients may be achievable.
Whenwe assessed the variability of tacrolimus exposure in
our clinic, we did not expect high variability to be identified
in our patients. However, data from 255 prospectively com-
piled patient records 1 year posttransplant confirmed signifi-
cantly higher rates of AR and graft loss for patients with
variability above the median of all levels between 6 and
12months posttransplantation, compared with patients with
variability below or equal to the median.75 In the first
6 months posttransplant, exogenous treatments with steroids
and antibiotics to treat graft failure, AR and infection are fre-
quently applied, and could affect tacrolimus levels by artificially
raising the variability of exposure. Further investigations of
data from 376 patients over a 4-year period confirmed the di-
vergence in graft survival between the higher-variability versus
lower-variability cohorts in our clinic, amounting to an ~12%
difference. Significant renal function benefits were also ob-
served in the lower- versus higher-variability cohort (n = 326;
rejection-free patients only). Analysis of DSA measurements
demonstrated that DSA-negative patients had significantly
lower tacrolimus variability profiles compared with DSA-
positive patients (n = 235; 16% versus 25%, respectively;
Figure 8 [M. Clancy, written communication, January 25,
2015]). Therefore, a possible explanation for the link between
higher variability of tacrolimus exposure and formation of
DSAs could be that fluctuations in the immunosuppressive reg-
imen allow a ‘break-through’ of the immune system.
With any data set or analysis it is important to recognize
the limitations when interpreting and applying the findings
to clinical practice. The data on variability of tacrolimus
exposure that are currently available have generally been
generated via retrospective analysis and covariation with
factors, particularly nonadherence, and are impossible to
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ence to tacrolimus improved by 10% when patients were
converted from immediate-release to prolonged-release ta-
crolimus.67 Converting patients from immediate-release to
prolonged-release tacrolimus preparations has been shown
to reduce intrapatient variability in both South Asian76 and
European populations.77 The clinical consequences of this
degree of improved adherence cannot be easily mapped, but
logically, a high-variability cohort should benefit in terms of
clinical outcome measures from a once-daily, prolonged-
release formulation of tacrolimus.
Prospective interventions to reduce intrapatient variability
start with the identification of patients with a high variability
of tacrolimus exposure. This can be achieved via a manual
calculation using a spreadsheet or via an app, such as the var-
iability calculator (Astellas Pharma Europe Ltd, UK), which
calculates variability (coefficient of variation) from tacroli-
mus trough measurements. Once patients with high variabil-
ity have been identified (according to the preset parameters in
the app or based on the clinic’s own cohort of patients), inter-
ventions could be beneficial. These interventions include edu-
cation on the impact of variability and nonadherence to
treatment, and conversion to prolonged-release tacrolimus,
which has been shown to have lower variability of exposure
and to improve adherence to treatment versus immediate-
release tacrolimus.67,77
High intrapatient variability of tacrolimus exposure defines
a group of patients proven to manifest rejection, graft failure
and dysfunction at a higher rate than the lower-variability pop-
ulation. Intervention to reduce variability would, therefore,
seem justified and sensible.More evidence to establish themag-
nitude of improvement in long-term outcomes, due to the
lower variability in tacrolimus exposure with the prolonged-
release versus immediate-release formulation is warranted.
However, based on the information currently available, con-
version to a once-daily tacrolimus preparation alongside addi-
tional supportive measures is a logical approach to reducing
intrapatient variability.
Underimmunosuppression in Kidney Transplantation
Dr Luís Guirado
Tacrolimus remains the cornerstone of immunosuppressive
treatments, with tacrolimus plusMMF and steroids being the
most commonly used regimen in kidney transplantation;
however, our understanding of immunosuppressive regimens
is evolving. Ten years ago, nephrotoxicity was considered to
be amajor risk factor and tacrolimusminimization was read-
ily discussed in an attempt to prevent kidney damage and
improve outcomes for our patients. We now understand
that the histologic lesions classically attributed to nephrotox-
icity are nonspecific and the main cause of these lesions is
alloimmunity.
In order to avoid nephrotoxicity, there is a temptation to
overminimize tacrolimus trough levels. Five-year posttransplant
graft survival data reported by the CTS show that if patients
are maintained on trough levels less than 5 ng/mL at year 1
posttransplant compared with trough levels of 5 to 7 ng/mL,
7 to 10 ng/mL and greater than 10 ng/mL, they are at higher
risk of graft failure (Figure 4).25 Patients with 1-year creati-
nine levels 130 to 250 μmol/L show improved renal function
5 years posttransplant; however, patients with 1-year serum
creatinine levels less than 130 μmol/L were found to havesimilar serum creatinine levels 5 years posttransplant regard-
less of tacrolimus trough levels. The 5-year findings reported
by the CTS for patients receiving tacrolimus plus MPAwith
serum creatinine levels less than 130μmol/L at 1 year demon-
strate that maintaining tacrolimus 5 ng/mL or greater versus
less than 5 ng/mL has a renal function benefit over 5 years of
treatment.25 CNI avoidance strategies, CsA in this example,
have also been associated with earlier and more frequent de
novo DSAs and an increased incidence of AR compared with
standard-dose regimens.38 Assessment of the development of
DSAs should also be checked at least once per year.
In our experience, patients who had inflammation in their
protocol biopsy had significantly lower tacrolimus trough levels
(P≤ 0.04)78 and higher blood creatinine levels (P = 0.003) ver-
sus thosewithout inflammation in their protocol biopsy. There
was a more pronounced difference in the high immunologic
risk patients (P < 0.001). A higher proportion of the patients
in the deceased donor group compared with the living donor
group had inflammation at 12 months posttransplant. We hy-
pothesize that this is due to the lower tacrolimus trough levels
(5-6 ng/mL) in this group and that 7 to 8 ng/mL of tacrolimus
exposure should be targeted after 1 year posttransplant.
The question remains, how can we minimize CNI nephro-
toxicity and preserve renal function without compromising
immunosuppression? We have established that maintaining
tacrolimus trough levels of 5 ng/mL or greater is crucial in
kidney transplantation. It is also essential to ensure consistent
tacrolimus exposure over time, as oscillating tacrolimus
levels could subject patients to overexposure of tacrolimus,
with the risk of toxicity, or underexposure, with the risk of
rejection. We found in our clinic that patients receiving
prolonged-release tacrolimus had lower intrapatient variabil-
ity of exposure versus patients receiving the immediate-
release formulation. This could have been, in part, due to
improved adherence. In the EVOLUTION study (EValuation
Of Advagraf conversion and Long-termUse in kidney Trans-
plantatION), for example, a 34% improvement in adherence
to tacrolimus was observed in the patients receiving the
prolonged-release versus immediate-release formulation.79
These findings were consistent with Stifft et al77 who re-
ported a 23% reduction in intrapatient variability after
conversion from immediate- to prolonged-release tacroli-
mus. Previously published studies have also demonstrated
a lower variability of tacrolimus exposure and improved
adherence to treatment with prolonged-release versus
immediate-release tacrolimus.76,77,80
Previously reported data from 40000 patients over 6 years
of follow-up suggest that there is an annual decrease in renal
function in the posttransplant period of ~1.6 mL/min per
1.73 m2 per year,81 with similar findings being reported for
4000 kidney transplant patients in the Catalan Registry
(−1.5 mL/min per 1.73 m2 per year). These data suggest that
even ‘stable’ patients are experiencing a decline in renal func-
tion over time and that we need to continue to monitor this
decline and to modify our therapeutic regimens to improve
outcomes for our patients. A number of recent publications
have found prolonged-release tacrolimus to be associated
with a reduction in renal function impairment compared
with the immediate-release formulation (Figure 9).82-84 We
speculate that this could be due to a more consistent phar-
macokinetic profile of prolonged-release versus immediate-
release tacrolimus.85
FIGURE 9. Mean serum creatinine concentration before and after con-
version from immediate-release to prolonged-release tacrolimus in kidney
or pancreas–kidney transplant patients.P values calculated using the
Student t-test. CI, confidence interval. Figure adapted with permission
from Kolonko A, Chudek J, Wiecek A. Improved kidney graft function
after conversion from twice daily tacrolimus to a once daily prolonged-
release formulation. Transplant Proc. 2011;43:2950–2953 doi:10.1016/
j.transproceed.2011.07.014. Adaptations are themselvesworksprotected
by copyright. So in order to publish this adaptation, authorization must
be obtained both from the owner of the copyright in the original work
and from the owner of copyright in the translation or adaptation.
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release to prolonged-release tacrolimus in the EVOLUTION
study79 showed that tacrolimus trough levels decreased by
10% immediately after conversion; however, postconversion
dose and trough levels remained stable over 12 months of
treatment. In these patients, renal functionwaswell preserved,
with a decrease lower than that of the general transplant pop-
ulation over the first year (−0.76 mL/min per 1.73 m2).79 AR
was low (0.4%) and 99.4%of patients reported a positive im-
pression postconversion.79 In the follow-up study, REVOLU-
TION (n = 1798),84 tacrolimus dose and trough levels were
maintained over a further 3 years of treatment. A significant
reduction in the intrapatient variability of tacrolimus trough
levels was reported at year 4 compared with month 0
(preconversion) (P = 0.01). Renal function decline remained
low compared with the general transplant population
throughout the follow-up.81,84 The difference between the ex-
pected and the observed annual decrease in renal function
over 4 years is both significant and clinically relevant to our
patients. The best practice care for our patients is to monitor
their renal function and to perform a protocol biopsy at 1 year
posttransplant. If patients do not have proteinuria but have
some degree of inflammation, it is likely that fibrosis will oc-
cur in the future and we should take steps to modify the risk
factors associated with underimmunosuppression, including
improving adherence to treatment and minimizing the vari-
ability of tacrolimus exposure. We are currently working to
identify biomarkers to identify patients with inflammation,
as inflammation is the principal cause of graft loss.
To conclude, tacrolimus plusMMF and steroids is the most
used combination of immunosuppressive drugs in kidney
transplantation. It is now accepted that nephrotoxicity is
much less frequent than first considered, and although there
is a general consensus that tacrolimus trough levels must be
maintained 5 ng/mL or greater, we need to move forward by
defining the optimal tacrolimus trough levels for our patients
in both the early transplant period and during maintenance
therapy. Tacrolimus avoidance or overminimization can in-
crease the development of DSA and humoral rejection, and
lead to poor graft survival. Prolonged-release tacrolimus helpsto maintain renal function79,82-84; this could be due to im-
proved adherence to treatment and decreased intrapatient var-
iability, and by maintenance of an adequate balance between
overimmunosuppression and underimmunosuppression.Cardiovascular Complications in Kidney Transplantation
Prof Bengt Fellström
While life expectancy posttransplant is improving in the
kidney transplant population, the incidence of cardiovascular
events remains largely constant; approximately 40%of deaths
with a functioning graft can be attributed to cardiovascular
disease in the first year posttransplant.86 Patients with chronic
kidney disease have an increased risk of cardiovascular disease
that increases with progressive renal dysfunction and peaks
during dialysis. Although the risk is lower posttransplant, pa-
tients still have a higher risk of premature cardiovascular dis-
ease compared with the general population.87
Risk factors for cardiovascular complications can be di-
vided into factors that exist before transplantation and fac-
tors that develop posttransplant. Pretransplant risk factors
include age, sex, previous cardiac and vascular disease, total
time on renal replacement therapy, smoking status, and hy-
perlipidemia. Posttransplant risk factors include left ventricu-
lar hypertrophy, hypertension, renal transplant dysfunction,
NODAT and hyperlipidemia. Some of these risk factors can
be modified by the immunosuppressive regimen and treat-
ments that are administered posttransplant.
Data from the United States Renal Data System database
show a prevalence of 42% of NODAT in kidney transplant
recipients.88 NODAT is associated with increased cardiovas-
cular risk and has a negative impact on graft function.89 Both
pretransplant diabetes andNODATare associatedwith signif-
icantly poorer patient survival compared with absence of dia-
betes.90 A number of immunosuppressive therapies, including
corticosteroids, tacrolimus, CsA and mammalian target of
rapamycin (mTOR) inhibitors, have been associated with a
higher risk of developing NODAT.91 The role of steroids in
the development of NODAT has been well established; data
from an analysis of greater than 25 000 kidney transplant re-
cipients demonstrated that patientswhowere receiving steroids
at the time of discharge fromhospital had a 42%greater risk of
developing NODAT.92 The management of patients with
NODAT follows the same stepwise approach applied to the
general population, including lifestyle and dietary modifica-
tions, pharmacologic therapy and patient monitoring.
Renal allograft decline and subsequent dysfunction are as-
sociated with an increased risk of cardiovascular events.
Fellström et al93 reported that elevated serum creatinine at
baseline was a strong and independent risk factor for major
adverse cardiac events (MACEs), and cardiac and all-cause
mortality. A correlation between graft loss and nonfatal myo-
cardial infarction was also reported. In a separate study of
1120295 adults (nontransplant), a decline in renal func-
tion was associated with an increased risk of the occur-
rence of cardiovascular events.94 Glomerular filtration
rates (GFRs), estimated by themodification of diet in renal dis-
ease (MDRD) formula, of 15 to 29 and less than 15 mL/min
per 1.73 m2 in the absence of dialysis, were associated with a
higher incidence of age-adjusted mortality.94
Hyperlipidemia has also been studied for cardiovascu-
lar complication in kidney transplantation. In the ALERT
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density lipoprotein cholesterol was associated with an in-
creased incidence of nonfatal myocardial infarction.95
Long-term benefits of statin therapy were demonstrated in
the trial, leading to changes in best practice and the imple-
mentation of early treatment for patients with high choles-
terol to be included in guidelines for the management of
renal transplant recipients.96
The influence of immunosuppressive drugs on cardiovas-
cular risk factors has never been systematically estimated,
although from a semiquantitative evaluation it has been sug-
gested that corticosteroids, tacrolimus and CsA influence hy-
pertension, hyperlipidemia and NODAT, whereas drugs like
MMF and monoclonal antibodies seem to be quite neutral
with regard to cardiovascular risk.87 Inflammation may have
an impact on cardiovascular risk in kidney patients. Data
from the ALERT trial demonstrated that biomarkers such
as interleukin-6 and C-reactive protein have a direct associa-
tion with increased cardiovascular risk.97
The Framingham risk factor model has not been validated
in kidney transplantation and, owing to the multifactorial
specificity of kidney transplant patients, it is not considered
to be applicable for calculating cardiovascular risk in these
populations. Therefore, there is an ongoing need for the de-
velopment of a risk factor calculator that is specific to kidney
transplantation. The MACEs risk calculator that we devel-
oped comprises a 7-variable model (age, previous coronary
heart disease, diabetes, low-density lipoprotein, creatinine,
number of transplants, and smoking status), and the mortal-
ity risk calculator comprises a 6-variable model (age, previous
coronary heart disease, diabetes, creatinine, total time in renal
replacement therapy, and smoking status).98 These risk factor
models were calibrated using theHosmer–Lemeshow test, ap-
plied to a data sample from the ALERT trial, and validated
using data from the PORT study (Patient Outcomes in
Renal Transplantation).98
These risk factor equations were applied to the BENEFIT
(Belatacept Evaluation of Nephroprotection and Efficacy
as First-line Immunosuppression Trial) and BENEFIT-EXT
studies (BENEFIT-EXTended criteria donors), to estimate
MACE and mortality in patients enrolled in the belatacept
LI (less intensive) and CsA arms.99 Over 7 years, the model
predicted that patients treated with belatacept would result
in a significant reduction in mortality in BENEFIT (5% abso-
lute reduction) and BENEFIT-EXT (5.64% absolute reduc-
tion) versus CsA. As expected, owing to the use of ECDs in
the BENEFIT-EXT study, a lower incidence of MACE was
predicted in the BENEFIT (3.40% absolute reduction) versus
the BENEFIT-EXT trial (4.88% absolute reduction).
Risk factor equations, with appropriate validation, may
provide us with useful insights into the long-term potential
of different treatment regimens in the absence of long-term
clinical trials. Taken in context with clinical trials and real-
world data, including registry data, these calculations could
help us to better determine the best practice care in kidney
transplantation. An adequately validated risk predictor may
also be used for individual counselling of kidney transplant
patients in an attempt to reduce cardiovascular risk, but this
application requires clinical judgment and depends on the
context for each patient.
In conclusion, renal transplant recipients have an increased
risk of cardiovascular events, but the risk is lower than forpatients who remain on dialysis. Risk associated with cardio-
vascular disease is complex to predict and each factor needs
to take into account a number of different parameters, includ-
ing age and gender. Additional research is needed to further
explore the specific risk factors for posttransplantation car-
diovascular disease, and recommendations for best-practice
management and treatment of these are still required. In the
meantime, some of the cardiovascular risk factors are modi-
fiable, and by choosing the optimal treatment regimens we
can improve the long-term outcomes for our patients.
The Liver Graft Journey and Risk Management
Prof John O’Grady
Liver transplantation has the ability to restore many decades
of health to patients with a range of life-threatening conditions.
The concept of the graft's journey captures the challenges fac-
ing the organ if it is to deliver its full potential. In this overview,
the journey is divided into 7 components, ranging from the
point of implantation to the time the organ ceases to function,
ideally after taking the recipient to an age that fulfils normal
life expectancy for that individual. A number of the issues
are considered in more depth in the chapters that follow.
Implantation
Primary nonfunction and poor early dysfunction represent
suboptimal starts to the graft journey. Primary nonfunction
appears to be occurring less frequently than in previous
years, but when it occurs, the management remains immedi-
ate retransplantation. There are numerous associations with
poor early graft function, including severe steatosis, pro-
longed cold ischemia time and donation after cardiac death.
Extracorporeal machine perfusion, including normothermic
and hypothermic techniques, is beginning to show promise
in improving early graft function and is potentially a major
advance for the future.
Establish Immunologic Stability
The initial immunosuppression regimen aims to achieve
immunologic stability of the graft. A CNI-based approach
using lower doses than historically practiced is now broadly
accepted as standard. Biologic agents are sometimes used as
routine therapy, but more frequently as an adjunct to reduced-
dose or delayed exposure to CNIs. One or 2 additional drugs
are typically included in the initial regimen. There is increasing
acknowledgement that the rate of acute cellular rejection
(ACR) in the first 10 days is not an appropriate metric of the ef-
ficacy of the initiating immunosuppression strategy.
Maintain Immunologic Stability
It has been stated that protocol immunosuppression is
largely an outdated concept.100 Instead, maintenance immu-
nosuppression is personalized to reflect the needs of individ-
ual patients, balancing good graft function with the lowest
achievable profile of side effects attributable to the totality
of the immunosuppression as well as the individual agents
being used. It is also en vogue at present to minimize the dose
of the CNIs, a practice that has, to a large degree, been driven
by a desire to protect renal function over the long term. There
was no evidence that this approach increased the risk of
chronic rejection and the incidence of ACR was only in-
creased when CNIs were avoided.101 There are theoretical
concerns that unintended consequences of minimization of
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through AMR, plasma cell hepatitis and idiopathic fibrosis.Address Technical Complications
Of all the elements of the journey, this is the one that is cur-
rently the least active in delivering improved outcomes. Stric-
ture formation at the site of the biliary anastomosis is the most
frequently encountered technical complication. Detection is
typically by magnetic resonance cholangiography, which is
followed by evaluation of clinical significance using direct chol-
angiography and possibly liver biopsy, particularly if surgical
reconstruction is being considered. Primary management is
usually balloondilatation and stent placement,with surgery be-
ing reserved for persistent stricturing. Diffuse cholangiopathy
complicates microvascular and macrovascular injury or re-
currence of primary sclerosing cholangitis. Management is
challenging and more severe cases require retransplantation.
Vascular complicationsmay involve any of the anastomosed
vessels. The most significant is hepatic artery thrombosis and
the earlier it occurs after liver transplantation, the more likely
the need for retransplantation. Graft infarction, liver abscesses,
and ischemic cholangiopathy represent 3, usually discrete,
manifestations of arterial thrombosis. Venous outflow compli-
cations are more likely with caval preservation techniques.Prevention of Recurrent Disease
This has been the most significant of the challenges to the
functioning graft. However, there is a strong expectation that
HCV, which was the most challenging of the recurring dis-
eases, will be effectively managed with the emerging direct-
acting antiviral agents.102,103 Affordability rather than efficacy
is the immediate concern in this regard. Alcohol-related and
non-alcohol-related fatty liver disease and the autoimmune
diseases are the next most important of the diseases with
the potential to recur.Within these aetiologies there is consid-
erable variation in the risk and clinical consequence of the
recurrent disease; HCC recurs in about 15% of patients, de-
spite careful selection, and is rarely amenable to therapy.Management of Drug-Related Toxicity
In addition to the generic burden of immunosuppression,
there is a range of toxicity profiles that have the potential to im-
pact on the graft journey. Historically, CNI-related nephrotox-
icity has been the exemplar of this consideration because of
apparent causative association, coupled with potentially seri-
ous outcomes. A sophisticated response strategy has emerged
that starts in the immediate posttransplant period and runs
throughout the journey of the graft. It begins with delayed or
reduced exposure to the CNI and continues with individual-
ized dosing regimens that give priority to the long-termmainte-
nance of good renal function. The latter includes attention to
other processes that contribute to loss of renal function, with
hypertension and diabetes mellitus being leading examples
(drug toxicity contributes independently to both). The risk of
cardiovascular disease is another dimension of these side effects,
in addition to dyslipidemia and obesity. The risk-management
strategy for cardiovascular disease is less well defined but is
likely to be modifiable with intelligent utilization of the ther-
apeutic options for effective immunosuppression.Death With a Functioning Graft
The ultimate hope for a transplanted organ is that it helps
sustain the life and health of the recipient until at least normal
life expectancy is realized. This has been achievedmany times
for individuals, but it is only recently that evidence has
emerged to indicate that it is becoming a realistic ambition
for some patient cohorts. A single-center, 20-year follow-up
study indicated that patients over 55 years of age who were
alive 1 year after liver transplantation had life expectancies
comparable to the normal population.104 At present, the
greatest shortfall in life expectancy in the first 20 years is in
those aged 30 to 55 years at the time of transplantation.
The 4 main causes of premature mortality are recurrent dis-
ease, infection, malignant disease and cardiovascular disease.
The expectation for the future is that each of these will grad-
ually reduce in importance until the aspiration of delivering
normal life expectancy is routinely realized.Donor-specific Alloantibodies in Liver Transplantation
Dr Jacqueline G O'Leary
The liver is relatively resistant to acute AMR compared
with other solid organs transplanted.105,106 This resilience is
facilitated by numerous mechanisms, but several are of criti-
cal importance. The liver’s size, affording it a 100-fold micro-
vasculature compared to the kidney, regenerative capacity,
ability to secrete soluble class I antigen, and the existence of
hypocomplementemia (secondary to liver dysfunction) serve
to mollify the effects of preformed DSAs. Furthermore, even
in the presence of injury, immune complexes and activated
complement are phagocytized by Kupffer cells. However, in
cases when acute AMR does occur in liver transplantation,
it is associated with poorer clinical outcomes.4
Despite the rarity of acute AMR, it can now be definitively
diagnosed. Key histopathologic characteristics include portal
vein endothelial cell hypertrophy, portal eosinophilia and eo-
sinophilic venulitis (Figure 10).106 The presence of lymphocytic
portal inflammation and lymphocytic venulitis without the
aforementioned features favours cellular rejection as opposed
to combined cellular- and AMR; acute AMR is almost never
found in isolation. In 1 retrospective, multicenter study, evalu-
ation for these key features using the acute AMR score allowed
for acute AMR determination with 81% sensitivity and 71%
specificity.106 However, when acute AMR is suspected, one
must also test for DSA, stain for C4d, and rule out other causes
of a similar injury pattern.107 Clinical features, such as falling
platelets (secondary to consumption) or otherwise unexplained
graft dysfunction, should also trigger suspicion.
Fortunately, most patients with preformed DSA have un-
eventful resolution posttransplant; even patients with class II
DSA with mean fluorescence intensity greater than 10 000
by single-antigen bead analysis (One Lambda, LABScreen,
US) experience resolution two-thirds of the time.108 After
transplant, the risk for de novo DSA in the first year ranges
from 0% to 8%, but when it occurs, the risk of death is dou-
bled.4 Some risk factors for de novo DSA formation include
the immunosuppression used (tacrolimus-based regimens have
the lowest risk), adherence to the regimen, age of the patient
and MELD score at transplant.4
Although acute AMR only affects ~1% of liver trans-
plants, chronic AMRmay be occurringmore commonly. Sev-
eral groups have reported an increased incidence of occult
FIGURE 10. (A) Endothelial cell hypertrophy, (B) portal vein eosinophilia, and (C) eosinophilic venulitis are 3 characteristic findings in a patient
with antibody-mediated rejection postliver transplantation. PV, portal vein; BD, bile duct. Figure adapted with permission from O’Leary JG,
Michelle Shiller S, Bellamy C, et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological
features. Liver Transpl. 2014;20:1244–1255 doi:10.1002/lt.23948.
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atric liver transplant, DSA+ versus DSA− patients are more
likely to develop advanced fibrosis on protocol biopsy.110
DSA+ versus DSA− HCV viremic patients had a tripling in
their risk of advanced fibrosis by 1 year posttransplant.112
In patients >6 months posttransplant, 9% of DSA−patients
developed de novo DSA, one quarter experienced acute
AMR, and even HCV-negative patients with DSA (versus
without) had more advanced fibrosis.109 Diagnostic criteria
for chronic AMR have recently been proposed for the identi-
fication of liver allograft recipients with DSA at higher risk
for allograft loss.117
When attempting to identify DSA+ patients at highest risk
for overt problems, several factors have been elucidated.
The quantity of alloantibody likely plays a role, in both
preformed and de novo DSA at the population level, but,
given the qualitative nature of current testing, this is difficult
to pinpoint.4,105,107,108,118 IgG3 subclass testing versus stan-
dard DSA testing better predicted the risk for death in a large,
single-center, retrospective analysis of preformed and de
novo DSA.119 Further supporting this concept, in a pediatric
weaning trial, some of the 12 tolerant patients had DSA but
none had IgG3 DSA.120,121 In addition, the presence of an
HLA and a non-HLA DSA may increase the risk for fibrosis
progression. A small pediatric liver allograft study demon-
strated that patients without DSA had the lowest risk of ad-
vanced fibrosis, those with either an HLA or angiotensin II
type 1 receptor (AT1R) autoantibody had an intermediate
risk, and all patients with bothHLADSA andAT1R antibod-
ies developed advanced fibrosis.111 In summary, patients athigher likelihood of developing progressive problems in the
face of DSA posttransplant include those with: (1) a higher
quantity of HLA DSA (which is difficult to measure with to-
day’s technology); (2) IgG3 subclass-positive DSA; (3) those
with an additional injury, such as HCV infection, that can
upregulate class II expression in the liver and thereby facilitate
binding with crosslinking to allow injury to occur117; and
(4) possibly those with both HLA and non-HLA antibodies.
Unfortunately, at the present time, liver biopsy is still
needed to determine if injury is occurring in patients with
DSA in serum. However, in the future, we hope biomarkers
will be used to examine patients’ risk for de novoDSA forma-
tion and injury in the face of posttransplant DSA, and, more
importantly, evaluate the risk of immunosuppressionminimi-
zation. Although simplistic, perhapsDQmatching could help
with risk stratification; patientswho are DQ-matched to their
donor may be at the lowest risk for de novo DSA formation
and, therefore, I hypothesize, at a lower risk for immunologic
complications with immunosuppression minimization, al-
though this hypothesis requires evaluation.On the other hand,
class II DSA may possibly be used as a biomarker of
alloimmune reactivity, potentially indicating the need formore
intense immunosuppression, although, once again, this hy-
pothesis has never been tested and will require formal evalua-
tion. As a result, the next step toward evaluating these
hypotheses will be to implement ‘standard protocol’ class II
DSA testing, with biopsies when positive, in all immunosup-
pression trials and into standard of care in centers with a re-
search interest in further understanding the role of DSA in
liver allograft fibrosis and function.
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chronic AMR on liver allografts is rapidly evolving, and we
will be better positioned to predict long-term outcomes of
our patients once multicenter studies with protocol DSA test-
ing and biopsies have been performed. At the present time,
immunosuppression regimens should not be adjusted based
on DSA data alone. Risk stratification pretransplant can be
accomplished to some degree through pretransplant DSA
testing, although some do not feel this is a cost-effective ap-
proach given the low prevalence of acute AMR. However,
of greater prevalence than acute AMR is the emerging con-
cept of chronic AMR associated with posttransplant DSA
and occult fibrosis progression, usually in the face of a nor-
mal or near-normal liver injury test. Ultimately, the most
cost-effective approach to improving outcomes from de novo
DSA is not through testing, but though prevention. Fortu-
nately, compared with CsA-based regimens, adherence to a
tacrolimus-based immunosuppression regimen is associated
with the lowest risk of developing de novo DSA.4Early Allograft Dysfunction and Biliary Strictures After
Liver Transplantation
Prof Jacques Pirenne
In liver transplantation, 2 complications, early allograft
dysfunction (EAD) and biliary strictures (BS), correlate with
increased hospital stay and/or hospital readmissions, inferior
graft and patient survival, and increased costs.122 Both condi-
tions are the end result of a cascade of tissue injuries that pre-
cede transplantation (preexisting disease in the donor, brain
death-induced injury, surgical trauma, cold preservation
and warm ischemia) and culminate in IRI in the recipient.
Bymodifying these risk factors and preventing organ damage
we have the potential to improve the results of liver trans-
plantation and widen its application by increasing the pool
of organs suitable for transplantation.
The incidence of EAD in liver transplant recipients is
approximately 25%.123 In a single center cohort, we found
the use of imported livers, the use of histidine-tryptophan-
ketoglutarate (HTK) as a preservation solution, high MELD
scores, and longer cold ischemia time to be risk factors for
EAD.122 The incidence of BS in livers from deceased and liv-
ing donors varies widely, from 4% to 40%.124 Risk factors
include donation after cardiac death, donor age, prolonged
warm and cold ischemia time, and extended use of vasopres-
sors in the donor.125
There are a variety of interventions that can be considered
in the prevention of EAD and BS. Modification of these risk
factors should begin during preretrieval of the organ for
transplantation and continue through procurement, pre-
servation of the organ and posttransplantation. Transplant
teams classically aim to procure organs rapidly to avoid
sustained brain death-induced inflammation. Recent studies
in kidney transplantation suggest that delaying procurement
after brain death is beneficial for organ recovery,126 as this al-
lows anti-inflammatory mechanisms to become activated.
Whether this strategy (“relax and repair” instead of “rush
and retrieve”)126 is also valid in liver transplantation is still
to be confirmed. A recent clinical trial demonstrated that
the use of steroid therapy in deceased donors reduces IRI
and biliary injury, and improves graft function.127 The ad-
ministration of an infusion of N-acetylcysteine before andduring procurement has also demonstrated efficacy in im-
proving graft survival in liver transplantation.128
During procurement, organ manipulation, which can in-
duce liver injury,129 should be minimized. Rapid extraction
is deemed necessary to prevent rewarming of the organ after
perfusion, since prolonged extraction time has been linked
to early graft failure in kidney transplantation.130 The use
of a double-perfusion strategy (aortic and portal flush) has
been shown to be beneficial for suboptimal livers, reducing
graft primary dysfunction and increasing patient and graft
survival.131 The incidence of BS has been reduced through
the use of low-viscosity preservation fluids, fluid pressuriza-
tion, and the addition of urokinase to the preservation solu-
tion and in the hepatic artery.132-134
Data from the ELTR suggest that the University of
Wisconsin, Celsior and IGL-I preservation solutions perform
better than HTK, the latter being associated with a 10% in-
crease in the risk of graft loss.135 In animal models, the addi-
tion of trophic factors to preservation solutions improves
organ function immediately posttransplant.136 In human
liver transplantation, the administration of a pan-caspase in-
hibitor to the preservation solution has been shown to result
in lower transaminase levels.137 Cold storagemay be suitable
for low- and normal-risk organs, but the time taken to reach
4°C and the low, yet persistent, level of metabolism at this
temperature causes tissue trauma in the absence of oxygen.
However, it has also been shown that toward the end of cold
storage, retrograde oxygen perfusion reduces EAD.138
In recent years, the field of organ preservation has been rev-
olutionized by the development of hypothermic machine per-
fusion (HMP) and normothermic machine perfusion (NMP).
In kidney transplantation, HMP reduces the incidence of
DGF and improves graft survival.42 In a porcine study, con-
tinuous HMP reduced hepatocyte injury but also led to an
increase in Kupffer and sinusoidal endothelial cell activa-
tion, which could eventually result in poor long-term graft
survival.139 However, improved results may be achieved
through the use of postcold-storage HMP.140 The big ques-
tion is whether HMP techniques will reduce the incidence
of BS. Studies in pigs and rats have shown a reduction in
arteriolonecrosis of the peribiliary plexus141 and reduced
intrahepatic biliary fibrosis,142 but these results need to be
confirmed in the clinic through RCTs. In NMP, the liver is
kept alive ex situ by perfusion with warm oxygenated blood.
A recent study used continuous NMP from procurement to
transplantation in pig liver transplants, resulting in good
posttransplantation survival even after 20 hours of warm
preservation.143 The use of continuous perfusion is thought
to be necessary because NMP is less effective after cold stor-
age. Ongoing trials are studying whether this strategy can re-
duce the incidence of EAD and BS.
Organ management in the recipient is also an important
consideration when attempting to mitigate IRI. The adminis-
tration of thymoglobulin to liver transplant recipients has
resulted in a reduction in transaminase levels.144 There is cur-
rent uncertainty regarding whether the use of erythropoietin
derivatives would be beneficial145; however, the use of
antiselectins appears to reduce IRI after liver transplanta-
tion.146 There is also the potential to use inhaled nitric oxide
to recover liver function posttransplantation,147 whereas an-
other intervention that could be worth consideration is the
use of mesenchymal stem cells, which have been shown to
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against liver IRI in animal models.149
While a number of these interventions look promising in
initial trials, using single compounds may not be an effective
approach to prevent EAD and BS that are multifactorial in
origin; instead, the use of multiple strategies targeting multi-
ple mechanisms could be more useful. One study demon-
strated this by targeting multiple mechanisms of IRI in pig
livers donated after circulatory death. The multifactorial
treatment resulted in the elimination of primary nonfunction
in recipients, reduced inflammation, improved liver function
and increased recipient survival. This technique also showed
potential in reducing the incidence of BS, as signified by a re-
duction in the biliary bile salt-to-phospholipid ratio, a surro-
gate marker for bile duct injury.150
In conclusion, EAD and BS remain major risk factors for
poor graft survival in liver transplantation. However, there
are some known risk factors that can be adjusted and inter-
ventions that can be used tomitigate them in clinical practice.
Some strategies are already available and should belong to
the standard of care for our patients, and some are in devel-
opment, but it is important that interventions be applied at
each step of the transplantation process.Adherence, or Lack of it, After Liver Transplantation
Prof John O’Grady
The requirement to take immunosuppressive therapy on a
regular basis to maintain liver graft function is a basic as-
sumption of clinical practice. Patient-driven nonadherence
with this commitment occurs more frequently than clini-
cians tend to believe and can be very difficult to detect. It also
may have no immediate consequence and this reinforces the
practice in patient behavior. Clinicians can be blinded to delib-
erate nonadherence by the practice of taking medication im-
mediately before a clinic visit. On the other hand, patients
may be unaware that some aspect of their behavior that does
not comply with protocol could be detrimental to their graft.
The immunosuppression regimen is specific for drug doses
but also for the intervals between doses and issues such as the
relationship to food. Clinicians are probably naïve in their
expectation of their patients’ ability to comply with this reg-
imen and nonadherence is more prevalent than assumed.60
The scale of deviation from the intended regimen is broad;
any deviation is classified as nonadherence. The clinical con-
sequence of this nonadherence is variable and may not di-
rectly correlate with the degree of deviation from protocol.
Detection of nonadherence relies on a combination of en-
quiry and investigation. Simply asking every patient how good
they are at taking their medication is an important starting
point. When nonadherence is suspected but not acknowl-
edged, information may be gained from drug levels in the
blood, pill counts, prescription patterns and electronic moni-
toring. Nonadherence varies with time of day and day of the
week; morning doses are less likely to be missed and the peak
time for nonadherence is Saturday evening.67
The profile of the nonadherent patient should be consid-
ered unpredictable, but younger patients and those with a
history of substance abuse or poor life satisfaction may be
at particular risk. However, the classic association is with ad-
olescence, with some estimates being in excess of 50% non-
adherence. It is considered to be a downside of maturationas the process of developing autonomy, separating from par-
ents and assimilating with peers progresses.151
Education and convenience of the immunosuppressive
regimen are core to the cause of promoting drug adherence.
The latter is aided by the least possible number of medica-
tions and time points during the day when these need to be
taken. An illustrative study demonstrated that conversion
from twice-daily tacrolimus to the modified-release prepara-
tion taken once daily resulted in a more than 50% reduction
in nonadherence.152
There are a range of responses to nonadherence once it has
been identified. These generally have cognitive, behavioral
and affective dimensions, as well as health care interventions.
These were assessed by a meta-analysis of 12 studies that en-
rolled between 18 and 110 patients. No one intervention was
considered superior and a combined approach seemed to be
most effective. However, it was noteworthy that the health
care interventions had the least impact.153 These findings in-
dicate that preventing the pattern of behavior that fosters
nonadherence is preferable to trying to reverse deviation
from disciplined practice.
There may be some ambivalence amongst clinicians re-
garding the importance of total adherence to the prescribed
immunosuppressive regimen. This may be reflected in an ap-
proach that reflects the perceived risk of nonadherence to in-
tervention being triggered by events such as unexplained
graft dysfunction or wide variability in blood levels of immu-
nosuppressive drugs. However, when graft function is good,
this approach permits a degree of nonadherence. The more
proactive approach to monitoring adherence is based on
the belief that stable long-term immunosuppression is the ba-
sis for successful liver transplantation.
ACR is the most obvious consequence of nonadherence.
Late ACR episodes are more difficult to treat than similar ep-
isodes occurring within the first 10 days of transplantation.
There are other less certain but potential consequences of er-
ratic immunosuppression, for example, AMR, plasma cell
hepatitis and idiopathic fibrosis. These issues are deserving
of further study, but in the meantime, it seems prudent to
advocate stable immunosuppression strategies as the most
effective protection.
Variability of Tacrolimus Exposure in
Liver Transplantation
Dr Varuna Aluvihare
Data show that early posttransplant patient and graft
survival continues to improve, although little progress has
been made on late (>5 years) survival.2Watt et al154 demon-
strated that, excluding year 1 mortality, two-thirds of all-
cause mortality is not directly related to the transplanted
liver. The significant contribution of nongraft mortality to
death in late transplantation104 is, therefore, one of our
biggest challenges.
Both interpatient and intrapatient variabilities of tacroli-
mus exposure posttransplant is well established, but its impli-
cations for liver transplant recipients compared with kidney
transplant recipients are less well characterized. Variability
of tacrolimus exposure is often determined by differences in
trough levels over time, or the standard deviation around
the mean, and data are available that demonstrate that tacro-
limus is associated with both interpatient and intrapatient
variability of exposure.155-158
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Interpatient variability is, in part, due to polymorphisms
that affect bioavailability of tacrolimus (eg, in the cytochrome
P450 system and the P-glycoprotein expression system, which
impact on tacrolimus metabolism and absorption, respec-
tively) and this is particularly relevant in certain ethnic
groups.156,157,159 Although interpatient variability is well es-
tablished, data relating to its impact on clinical outcomes
are scarce.
Intrapatient Variability of Tacrolimus Exposure
In our center, we studied 64 patients converted early
(≤1month) and 65 patients converted late (>1month) postliver
transplant from immediate-release to prolonged-release ta-
crolimus. These data were compared with 60 patients who
remained on immediate-release tacrolimus. Using dose-
normalized tacrolimus trough levels, lower interpatient vari-
ability was observed at all time points with early posttransplant
conversion compared with late conversion or continuation on
the immediate-release tacrolimus formulation. This difference
was maintained over 6 months of treatment. The study also
demonstrated that intrapatient variability was lower with
prolonged-release versus immediate-release tacrolimuswith late
posttransplant conversion.160 These data are supported by
other published studies that show a reduction in variability of
tacrolimus exposure with prolonged-release versus immediate-
release tacrolimus.161,162
In a study assessing intrapatient variability in a pediatric
population of 101 patients, a standard deviation greater than
2 around the mean tacrolimus trough level was associated
with late allograft rejection.163 Another study described a
“medication level variability index” (MLVI); MLVI was de-
fined as the standard deviation of tacrolimus blood levels
for each patient fromaminimumof 4 readings during the study
period. Not only was theMLVI associated with rejection, it ac-
tually predicted it,164 making this method a robust measure of
consistency of exposure. A reduction in interpatient and
intrapatient variability may, in part, contribute to the signifi-
cant improvements in graft and patient survival achieved with
prolonged-release versus immediate-release tacrolimus that
have recently been described.18 Unfortunately, variability of ta-
crolimus exposure was not formally analyzed alongside the
clinical findings in the ELTR study.18
It is well known that nonadherence to treatment is a risk
factor for poor long-term outcomes in solid-organ transplan-
tation. Our data indicate that converting patients who have
had poor medication adherence with twice-daily, immediate-
release tacrolimus to once-daily, prolonged-release tacrolimus
improves adherence and clinical outcomes. It is noteworthy
that few clinical programs proactively monitor nonadherence.
Treatment is, therefore, often only initiated when prolonged
nonadherence has precipitated graft dysfunction, by which
time graft damage has already occurred. Furthermore, the pat-
tern of nonadherence is likely well established and long-lasting.
Bioequivalence of Tacrolimus Formulations
Emerging data indicate that different tacrolimus formula-
tionsmay have differential effects on rejection and renal func-
tion, potentially impacting long-term outcomes. In addition
to the innovator drugs of immediate-release and prolonged-
release tacrolimus, generic versions of the immediate-releaseformulation exist. In order for the generic formulations to
be available in clinical practice they have to be shown to be
bioequivalent to the innovator drug. However, there is a lack
of consensus as to what constitutes bioequivalence in differ-
ent countries, which is of particular significance when con-
sidering drugs with a narrow therapeutic index, such as
tacrolimus. Furthermore, these studies have been performed
on healthy volunteers rather than transplant patients, and
do not take into account differing posttransplant drug regi-
mens, gastrointestinal function and clinical course. Given
the above, the potential for unanticipated clinical events de-
spite bioequivalence remains a concern, as does any impact
on interpatient and intrapatient variability. Heightened vigi-
lance and adequate therapeutic drug monitoring need to be
used andmore data on the impact of variability of tacrolimus
exposure needs to be obtained.
Summary
There is an urgent need to develop tests to stratify risk for
poor graft and patient survival in clinical practice. First, var-
iability of tacrolimus exposure needs to be more effectively
measured than is usual in clinical practice, where the last 2
or 3 measurements are usually considered. An electronic sys-
tem that notifies transplant physicians when a patient has a
high variability of tacrolimus exposure, before they present
with clinical symptoms, would be optimal. Better risk strati-
fication of nonadherence to treatment early posttransplant
needs to be developed. Barriers to adherence should be exam-
ined using existing resources; for example, we use a nurse-led
health promotion clinic specifically aimed at identifying and
treating nonadherence. Improved characterization of patient
phenotypes, including immune phenotypes defining the high-
risk recipient, needs to be developed. Finally, tacrolimus formu-
lations and drug regimens thatminimize variability of exposure
and improve adherence should be preferentially used.
Underimmunosuppression in Liver Transplantation
Dr Pavel Trunečka
CNIs remain pivotal to postliver transplantation immuno-
suppression. There is an abundance of literature comparing
the 2 CNIs, tacrolimus and CsA; generally, the finding is that
tacrolimus is superior to CsA in improving graft and patient
survival, and preventing AR after liver transplantation.165 In
2010, a study was published confirming the noninferiority of
efficacy for prolonged-release versus immediate-release ta-
crolimus,166 and since then, there has been evidence to sug-
gest that prolonged-release tacrolimus is associated with
graft and patient survival benefits for liver transplant patients
compared with the immediate-release formulation.18 Despite
the unquestionable improvements in posttransplantation im-
munosuppression since its inception, there remain some
drawbacks, especially with CNIs, including the potential for
metabolic and cardiovascular complications, and renal insuf-
ficiency. A decline in renal function is thought to be one of the
main causes of poor overall outcomes postliver transplant.
Data from the US National Institute of Diabetes and Diges-
tive and Kidney Diseases (NIDDK) liver transplantation da-
tabase suggest that the influence of renal failure on long-term
outcomes increases over time, with renal failure associated
with a hazard ratio of 7.5, >5 years posttransplant.154 Some
complications affecting long-term patient survival after liver
FIGURE 11. Renal function (eGFR (MDRD4)) at week 24 with differ-
ent prolonged-release tacrolimus-based regimens in liver transplant
patients. Data are based on the full-analysis set. P values were an-
alyzed by ANOVA. Arm 1: standard-dose, prolonged-release ta-
crolimus plus mycophenolate mofetil (MMF); Arm 2: lower-dose,
prolonged-release tacrolimus plus MMF and basiliximab; Arm 3:
standard-dose, prolonged-release tacrolimus (delayed until day
5) plus MMF and basiliximab. ANOVA, analysis of variance;
eGFR, estimated glomerular filtration rate; MDRD, Modification
of Diet in Renal Disease; MMF, mycophenolate mofetil. Adapted
with permission from Trunečka P, Klempnauer J, Bechstein WO,
et al. Renal function in de novo liver transplant recipients receiving dif-
ferent prolonged-release tacrolimus regimens—the DIAMOND study.
Am J Transplant. 2015;15:1843–1854 doi:10.1111/ajt.13182. Ad-
aptations are themselves works protected by copyright. So in order
to publish this adaptation, authorization must be obtained both from
the owner of the copyright in the original work and from the owner of
copyright in the translation or adaptation.
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regimens used,167 although data from the NIDDK suggest
that diligent management of modifiable factors, including di-
abetes, hypertension and renal insufficiency, could improve
long-term patient survival.154
The risk of impaired renal function and the need for renal re-
placement therapy in liver transplant recipients is thought to be
increasing due to the use of organs from ECDs and transplan-
tation in older patients with higher MELD scores. A recent
study usingmeasured and estimatedGFR (mGFR; eGFR) dem-
onstrated that decreased renal function is associated with a
trend toward increased risk of death, with that risk increasing
exponentially when GFR falls below 30 mL/min per 1.73 m2
(relative risk, 2.28-3.62).168 Results from this study also sug-
gest that creatinine-based calculations of eGFR underestimate
the mortality risk compared with mGFR.168
The immunosuppressive regimen used most commonly in
liver transplantation consists of tacrolimus in combination
with MMF, with or without steroids. It is important to
achieve the right level of tacrolimus exposure, as underexpo-
sure has been linked with reduced graft survival and patient
outcomes.169 The concept of underimmunosuppression
(or overminimization) is different in kidney and liver trans-
plantation. In kidney transplantation, chronic allograft ne-
phropathy, once considered a sign of CNI toxicity, is caused,
in part, by alloreactivity; therefore, minimization of tacrolimus
exposure intensifies the deleterious effect on the kidney. This
mechanism does not contribute to kidney failure in liver trans-
plant recipients because alloreactivity, due to inadequate sup-
pression, does not contribute to damage of the native kidney.
Therefore, historically, it was thought that to reduce any
CNI nephrotoxicity postliver transplant, the logical goal was
tominimize exposure to CNI. Rationale for CNIminimization
after liver transplantation came from 2 principal expectations
that are not well supported in scientific literature. The first as-
sumptionwas that exposure to CNI is themain reason for kid-
ney failure posttransplant and the second was that ACR after
liver transplantation does not harm the graft in the long term.
In terms of exposure, lowering the exposure to CNI can be
achieved by dose minimization or delaying the administra-
tion of CNI until several days posttransplantation. Data from
the ReSpECT study showed that patients receiving reduced-
dose (target trough level,≤8 ng/mL), immediate-release tacro-
limus delayed until day 5, in combination with daclizumab,
MMF and corticosteroids had less kidney impairment after
52 weeks compared with those receiving a higher-dose (target
trough level, >10 ng/mL), immediate administration of the
same formulation of tacrolimus (without daclizumab and
MMF).170 It was unclear from the results of the ReSpECT
study whether the reduced renal impairment was due to the
delayed administration of tacrolimus or the overall reduction
in exposure over time. The DIAMOND study (ADvagraf
studIed in combinAtion with MycOphenolate mofetil aND
basiliximab in liver transplantation) was designed to investi-
gate administration of prolonged-release tacrolimus-based
regimens further. The study design was similar to that of the
ReSpECT study, with 857 liver transplant recipients receiving
MMF and a single bolus of intraoperative corticosteroids,
in combination with one of the following: standard-dose,
prolonged-release tacrolimus (target trough level, 5-15 ng/mL
until day 42 then 5-12 ng/mL); lower-dose, prolonged-
release tacrolimus (4-12 ng/mL until day 42 then reducedby 20-25%) and basiliximab; or standard-dose, prolonged-
release tacrolimus (5-15 ng/mL until day 42) delayed until
day 5 and basiliximab.171 Results from this study indicated
that lower-dose, prolonged-release tacrolimus administered
immediately posttransplant (and a subsequent lower tacroli-
mus exposure over the first month), together withMMF and
basiliximab, was associated with a significant renal function
benefit and a significantly lower incidence of biopsy-confirmed
acute rejection (BCAR) versus the standard-dose, prolonged-
release tacrolimus-based regimen (Figure 11).171 Delayed
initiation of standard-dose, prolonged-release tacrolimus sig-
nificantly reduced renal function impairment; however, the
BCAR incidence advantagewas not seenwith delayed initiation
(Figure 11).171 Results from this study indicate that early tacro-
limus exposure in the immediate posttransplant period may be
critical in maintaining renal function over the long term.
An old view of ACR as a harmless or even protective event
promoting tolerance and long-term graft survival supported
the strategy of CNI overminimization.172 In light of the pos-
sibly deleterious effect of the association between DSA and
under immunosuppression, views regarding the role of
ACR changed; ACR is now less acceptable and this new per-
spective is supported by published literature.105,106,108 In a
study of 493 patients, those with tacrolimus trough levels
greater than 7 ng/mL,measured on the day of protocol biopsy,
experienced fewer moderate/severe rejection episodes during
the first 2 weeks posttransplant compared with those with ta-
crolimus trough levels 7 ng/mL or lower (Figure 12).169 Data
from this study indicate that trough levels of 7 to 10 ng/mL
are efficacious in preventing AR and are associated with
longer-term graft survival compared with patients whose
trough levels are outside that window.169 A systematic
FIGURE 12. Incidence of moderate/severe histologic rejection in
protocol biopsies of transplant recipients stratified by tacrolimus
trough concentration. Shaded box shows trough concentrations
≥7 ng/mL. Tacrolimus was administered immediately posttransplant
(0.1 mg/kg per day in 2 divided doses), after which the dose was ad-
justed according to blood trough concentrations and renal dysfunc-
tion or other side effects. Protocol biopsies were performed within
the first 15 days posttransplant. ACR, acute cellular rejection.
Reprinted with permission from Rodríguez-Perálvarez M, Germani G,
Papastergiou V, et al. Early tacrolimus exposure after liver transplantation:
relationship with moderate/severe acute rejection and long-term out-
come. J Hepatol. 2013;58: 262–270 doi:10.1016/j.jhep.2012.09.019.
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mus trough levels between 6 and 10 ng/mL during the first
4 to 6 weeks after transplantation could reduce renal impair-
ment without increasing the incidence of moderate/
severe ACR.173
Early immunosuppression seems necessary for optimal im-
munologic outcome in liver transplant recipients, especially
in light of the role of de novo DSAs and the association be-
tween DSAs, AR and graft loss. The concept of tacrolimus
minimization as a protective factor in liver transplantation
is not based on evidence or data from RCTs in liver trans-
plantation, but seemingly on traditional views of CNI-
related side effects (predominantly on kidney function). The
role of ACR in liver transplantation must be reevaluated, as
the implications seem to have a greater impact on long-term
outcomes than traditionally believed. Maintenance steroids
have been found to be generally unnecessary for the avoid-
ance of ACR in liver transplantation.171 Immunosuppressive
protocols should avoid early alloimmune reactivity; optimal
tacrolimus trough levels for a liver transplant recipient early
posttransplant are in the range of 6 to 10ng/mL,with limited ev-
idence for any beneficial effects of delayed administration of ta-
crolimus after transplantation in standard recipient populations.
Cardiovascular Complications in Liver Transplantation
Dr Umberto Baccarani
Liver transplantation is associated with an increase in car-
diovascular risk, ranging from 9.4% at 5 years to 25% at
10 years.174 Cardiac evaluation before liver transplantation is es-
sential to decrease mortality and to prevent new cardiovascular
diseases posttransplant. Themost commonpretransplant cardiac
condition affecting patients with liver cirrhosis is cirrhotic cardio-
myopathy. In addition, left ventricular outflow tract obstruction,
coronary artery disease (CAD), portopulmonary hypertension
and NODATare frequently recorded.
Cirrhotic cardiomyopathy is a cardiac dysfunction in pa-
tients with advanced liver disease, characterized by impaired
cardiac contractility and altered diastolic and systolic func-
tion with electrophysiological abnormalities.175 From theclinical point of view, it is characterized by hyperdynamic
circulation with increased cardiac output secondary to low
systemic vascular resistance and increased arterial compliance.
The potential impact of cirrhotic cardiomyopathy is re-
lated to the severity of liver disease, ending in cardiac fail-
ure when the patient presents with end-stage liver disease
and decompensated cirrhosis.
Plotkin et al176 reported a 50% incidence of mortality in
liver transplant recipients with a history of CAD (1- to 3-year
follow up). In patients over 50 years of age, a 27% incidence
of moderate or severe CAD was reported. Diabetes was the
most important predictive risk factor for CAD.177 An abnor-
mal noninvasive test or a high pretest probability of CAD
(≥2 classical risk factors) is an indication for coronary angiog-
raphy or cardiac computed tomography angiography.178
Patients with left ventricular outflow tract obstruction
may exhibit a poor tolerance to hemodynamic stress during
transplant179 and careful intraoperative monitoring with
trans-esophageal echocardiography is required to avoid
tachycardia. Limited use of inotropic agents and trans-
esophageal echocardiography-guided volume administration
is advisable to avoid overload of the right ventricle.
Hypertension is a primary consequence of immunosup-
pression and of renal disease. Recommendations for pa-
tient management comprise blood pressure monitoring and
early-onset treatment, as in the general population; for pa-
tients without proteinuria, anti-hypertensive therapy should
be initiated with a calcium channel blocker. Many patients
require combination therapy, with the addition of an angio-
tensin II receptor blocker or angiotensin-converting-enzyme
inhibitor. Early withdrawal of steroids posttransplant and
monitoring/modification of the immunosuppression regimen
is also recommended.
Metabolic syndrome has been described in 44% to 58% of
patients after 6 months posttransplant and it is associated with
increased cardiovascular and cerebrovascular events,180mainly
due to an increased prevalence of metabolic syndrome features
(diabetes, hypertension, and hyperlipidemia) posttransplant.180
Portopulmonary hypertension may affect 5% to 10% of
liver transplant candidates, resulting in poor long-term out-
comes. Before liver transplantation, patients need to be treated
with prostanoids, phosphodiesterase inhibitors and endothelin
receptor antagonists to modify this risk factor for poor patient
survival. The reported frequency of hepatopulmonary syn-
drome in patients with liver disease ranges between 4% and
29%.181 The treatment of hepatopulmonary syndrome in-
cludes the correction of hypoxemia by administration of oxy-
gen. Patients with hepatopulmonary syndrome typically have
normal or only mildly elevated pulmonary arterial pressure,
and liver transplant may be curative.
NODAT has been recognized as a clinically important
complication in liver transplantation. A stepwise treatment
to NODAT considers nonpharmacological therapy with life-
style modification plus education.182 If glycemia is not con-
trolled, monotherapy with an oral anti-diabetic medication
is considered. If individualized goals for glucose control are
not achieved in 2 to 4 months, a reassessment of lifestyle in-
terventions is required in addition to oral combination ther-
apy.182 Many studies have described the high prevalence and
incidence of dyslipidemia in patients posttransplant.183,184 Im-
munosuppressive treatment could affect lipid metabolism.180
Annual screening of a patient’s lipid profile, with treatment
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risk population, is recommended. For patients not responding
to dietary interventions, statins are recommended as first-line
agents. Therapy modifications are suggested for patients not
responding to drug therapy, including the conversion from
CsA to tacrolimus.185
Van Wagner et al186 analyzed the early cardiovascular
mortality of 1576 liver transplant recipients who died within
30 days of transplant. Using a logistic regression model, the
authors were able to develop a predictive model of early car-
diovascular mortality, finding 9 main predictors: 6 recipient
covariates (age, preoperative hospitalization, intensive care
unit requirement, ventilator status, MELD score and history
of portal vein thrombosis), 2 donor covariates (national or-
gan sharing, donor body mass index) and 1 operative covar-
iate (cold ischemia time).
Cardiovascular events are one of the most important
causes of morbidity and mortality postliver transplant. In
pretransplant patients, attention should be placed on identi-
fying subclinical cardiac events that influence early and
long-term outcomes. In patients with portopulmonary hy-
pertension, screening with transthoracic echocardiography,
confirmed by right heart catheterization, and treatment be-
fore liver transplant are recommended. Screening for CAD
is recommended for high-risk patients. Given poor sensitivity
and negative predictive value of noninvasive tests, coronary
angiography is recommended in the presence of >2 risk
factors. Transthoracic echocardiography before transplant,
for screening, and intraoperative trans-esophageal echo-
cardiography during transplant, for close hemodynamic sur-
veillance, are key examinations to monitor cardiac function.
There is an ongoing need for further research, potentially
using large-scale, real-world data sets, to continue to identify
the specific risk factors for the development of cardiovascular
complications posttransplant, and for these risk factors to be
prospectively managed, where possible, before the occur-
rence of a cardiovascular event.
Lifestyle modification is currently the first approach to re-
ducing cardiovascular risk. When therapeutic changes are
proven to be ineffective, modification of the immunosuppres-
sive regimen and specific medication should be considered.
PART 2: SOLUTIONS AND INNOVATIONS WITHIN
KIDNEYAND LIVER TRANSPLANTATION
Long-Term Patient Management
Optimizing Resource Allocation in Transplantation
Prof James Neuberger
Solid organ transplantation is expensive in terms of time,
expertise and other associated resources; the imbalance be-
tween need and availability of organs means there has to be
rationing of an intervention that improves both longevity
and quality of life. The limited data available suggest that,
in some countries at least, both volume and location of
transplant units could affect access to, and outcomes of
transplants.187-189 However, transplant units have often de-
veloped in an unplanned manner.
A national approach to patient selection and organ alloca-
tion is necessary to ensure an equitable use of resources,
although variation in acceptance rates of organs between cen-
ters and surgeons may lead to inequity of access to transplan-
tation. Monitoring of absolute and risk-adjusted outcomesfrom both listing and transplantation is necessary to en-
sure good governance and the best use of resources. How-
ever, care must be exercised so that monitoring does not
encourage inappropriate risk-averse behavior or inhibit re-
search, innovation or training. Optimizing resources, espe-
cially of donated organs, therefore requires consideration
of both the commissioning of transplant units and moni-
toring the outcome of donated organs.
Provision of Transplant Units
An efficient national transplant service requires an effective
program to ensure an adequate supply of donated organs, ac-
curate donor and organ characterization, an effective re-
trieval service, and the provision of transplant units that
operate in an ethical and legal framework with appropriate
levels of regulation, oversight and transparency. Each trans-
plant unit requires a skilledmultidisciplinary teamof surgeons,
physicians, intensivists, anesthetists, interventional radiolo-
gists, histopathologists, pharmacists, nurses, dieticians, and co-
ordinators. They must also be supported by specialists in
infectious diseases, and alcohol and substance abuse. The pro-
vision of transplant services should further be based on need,
available resources and geography; but in practice, units have
developed because of the enthusiasm of clinicians, and are sup-
ported by hospital managers who recognize the financial and
reputational benefits of a successful unit. Provision of organs
for transplantation and routine care in transplant units vary
considerably (Table 2), as do the outcomes achieved.190,191
Studies are conflicting as towhether transplant volume has
an effect on outcomes. There are more data relating to center
transplant volumes for liver transplant than for other organs.
An analysis of nearly 35000 liver transplant recipients in the
ELTR showed patients transplanted in centers performing 70
or more transplants/year had significantly better early out-
comes compared with patients transplanted in centers per-
forming less than 70 transplants/year.192 Another earlier
study found that outcomeswere better in patients transplanted
in centers performing more than 20 transplants/year versus
less than 20 transplants/year, whereas, a study by Nijboer
et al193,194 did not find a clear correlation between center ac-
tivity and outcomes in 24 liver transplant units in Germany.
In a similar US-based study,Macomber et al195 found lower
mortality rates in higher-volume centers, with lower median
length of hospital and intensive care unit stay and lower di-
rect costs. Others have failed to demonstrate an effect of
volume.196,197 The variation in conclusions as to the impact
of volume on outcomes could relate, at least in part, to the
impact of small numbers, the relative bluntness of risk adjust-
ment, the fact that some small-volume centers may be led by
very experienced surgeons trained elsewhere, and the experi-
ence with related surgical interventions.198 These figures,
however, do not take into account other activities, such as
living or deceased donors, liver resection and other solid or-
gan transplants. In conclusion, there is a suggestion that, for
optimal outcomes, a center undertaking adult deceased-
donor liver transplants should be performing at least 20 per
year, without evidence to suggest an upper limit beyond
which outcomes decline.
Geography and the Provision of Transplant Units
The provision of services is affected by geography, so dis-
tribution of units must reflect, in part, the population
TABLE 2.
Distribution of liver and kidney transplant units
Country
Liver
transplant units
Liver transplants
per million population
Liver transplant units
per million population
Kidney
transplant units
Kidney transplants
per million population
Kidney transplant units
per million population
United States 139 19.8 0.44 250 53.2 0.79
Spain 25 23.2 0.53 44 47.3 0.94
Germany 25 13.4 0.30 40 35.9 0.49
France 22 18.3 0.35 44 44.7 0.68
Italy 22 16.4 0.36 43 28.2 0.72
UK 7 13.0 0.11 27 44.0 0.44
Switzerland 3 13.0 0.39 6 37.7 0.77
Ireland 1 10.9 0.22 1 37.8 0.22
Data from Newsletter, Transplant International Figures on Donation and Transplantation.188,189
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to transplant services and outcomes, but the interaction is
complex and is affected by access to specialists, referral to
transplant units and variation in listing.187,199,200 This varia-
tion could reflect other factors, such as socioeconomic status,
ethnicity and burden of illness.201-206 Whether distance from
a transplant center affects the chances of getting a transplant
is uncertain,206,207 but travelling to a distant center may not
always benefit the patient.208
Does Choice Benefit the Patient?
Opinion is divided as to whether a competitive market
would increase choice and standards and drive down costs.
Several studies have suggested that competition among pro-
viders of liver transplantation has mixed effects: in the stud-
ies, centers with greater competition had a higher rate of
graft failure and patient death, used more high-risk grafts
and had longer waiting lists, but transplanted more of the
sickest patients and a greater proportion of the population
(although the latter was not statistically significant).209,210
Can Resource Allocation Ensure Equity of Access
and Outcomes?
In this context, equity means that patients with the same
characteristics (age, sex, geographical location, ethnicity, life-
style, financial resources, and disease and disease severity)
will have the same chance of being listed and being offered
a graft (or dying on the list), and will have similar outcomes.
There is no single measure of outcome, or consistency of
what outcome measurements are based upon, with some
based on outcome measurement of the patient and some on
outcome measurement of the graft. There is also lack of con-
sistency with respect to assessment initiation, with some
starting at the time of the patient being listed for transplanta-
tion, and others starting posttransplantation. Outcome mea-
surement, therefore, requires risk adjustment, but this is a
blunt tool and a failure to include all relevant data can pro-
duce misleading conclusions.211
Overreliance on outcomes in transplantation may encour-
age risk-averse behavior.211,212 Surgeons concerned about ad-
verse outcomes might be more likely to avoid circumstances
that could reduce their patients' survival rates, including the
avoidance of high-risk donors and recipients, not letting less-
experienced colleagues and trainees develop expertise, and
even a resistance to innovation. Avoiding high-risk donors will
increase the risk of death without a transplant, and deathwhile awaiting a transplant is just as lethal as death post-
transplant. A higher survival rate could, therefore, come at
the price of lower benefit. Publication of outcome data alone
could lead to distorted conclusions and could drive clinical
practice against the interests of the patient. Thus, patients
should be given information, both absolute and risk-
adjusted, about the outcomes for each center from listings
and from transplantation. While this seems a clear goal and
is carried out both in the UK (www.odt.nhs.uk) and the USA
(www.unos.org), it is practiced in few other jurisdictions.
Is National Allocation of Donated Organs the Best Use
of Resources?
There are complex algorithms for allocation of organs for
transplantation. In the United States, as in many other juris-
dictions, livers are allocated primarily on the basis of need.
This has been effective in reducing the mortality of patients
on the waiting list, but potentially at the expense of
increasing posttransplant resource utilization,213 and some-
times excludes from access those with conditions that make
life intolerable (intractable severe itching or chronic encepha-
lopathy). Kidney allocation tends to be more complex than
liver allocation, based on multiple factors, including waiting
time, blood group, sensitization, and age matching.
Both organ allocation and graft outcome monitoring must
not inhibit innovation and research. There is limited evidence
to suggest that centers supporting clinical research deliver
better clinical care; however, a national allocation scheme
based on need is confounded by variation in acceptance
rates.213-215 The appetite for risk-taking varies not only be-
tween, but also within units,210 and may be affected by over-
zealous outcome monitoring.212 Furthermore, the ability to
predict the donor-specific risk of graft failure is relatively
poor, with a systematic bias toward inaccurately low esti-
mates of graft failure, especially for higher-risk organs.216 Al-
location schemes are, in reality, offering schemes and because
centers vary in their use of organs, reliance on allocation can-
not achieve the best use of resource.
Clinical Innovation in Transplantation
Dr Philip F Halloran
The very success of organ transplantation presents us with
a host of problems and opportunities for improvement.
There are approximately 120000 new organ transplants
per year worldwide (available at: http://issuu.com/o-n-t/
docs/2012ad. Accessed 15 March 2016) and approximately
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bled and are in danger of failing. There are hundreds of thou-
sands of people on transplantation waiting lists and millions
more who could potentially benefit from organ transplanta-
tion.Meeting these challenges will require clinical innovation,
and part of the problem is the high level of organ transplant
attrition. Tens of thousands of organ transplants fail each
year andmanymore organs function suboptimally. Immuno-
suppressive regimens face the challenge of nonadherence to
treatment, which is responsible for the high rate of graft failure
involving AMR,57 and of delivery of affordable drugs in pop-
ulations where the cost of drugs is challenging.
Innovation is needed to provide more organs to meet de-
mand, new diagnostic techniques to identify the disease
states, a reduction in the burden of immunosuppression tox-
icity, and strategies to prevent and treat the main causes of
graft loss, including AMR, nonadherence to treatment, and
recurrent disease. Examples of how research could impact
these needs include the optimization of donor organ use
(and using currently discarded organs if possible), molecular
phenotyping, tolerance initiatives to reduce the need for
immunosuppression, and regenerative medicine applications
to create, engineer or repair organs for transplantation. In-
vestment from the pharmaceutical and biotechnology indus-
try will be critical, because grants from governments and
altruistic agencies are unlikely to be sufficient.
Improved utilization of donor organs must include more
effective identification and conversion of potential deceased
donors. We need more evidence to support the choices made
to use or discard ECD organs, avoiding the loss of useful or-
gans at a timewhen the need is so pressing.Molecular pheno-
typing probably offers the greatest opportunity to develop
that evidence. Measurements must address both the degree
of acute organ injury and the extent of biologic aging.
Opportunities to improve the availability of organs for
transplantation may be found in ex vivo perfusion, such as
the remarkable advances in ex vivo lung preservation,217
which has resulted in the use of many lungs that would have
previously been discarded. The use of discarded organs as
scaffolds shows promise and some groups continue to ex-
plore the potential applications of xenotransplantation, espe-
cially using genetically modified pig organs. The prospect of
monetary rewards for donation is an issue that should be
discussed, despite the deep divisions in opinion.
Precision medicine generally requires assessments that
identify heterogeneity in the disease states. This will re-
quire molecular phenotyping, as has been widely used in
cancer.218 Molecular biopsy interpretation can create
new disease classification, recalibrate the conventional
methods, correct errors, and reveal mechanisms that can be
targeted by new drugs. Improved disease classification will
empower the search for noninvasive biomarkers in body
fluids, which has been limited by inaccuracies in the current
diagnostic systems. To serve as screening tests, potential bio-
markers must be inexpensive and superior to existing tests,
such as urine dipstick testing for protein and serum creati-
nine. Distinguishing abnormal from normal is usually done
well by the current screening tests. The ideal biomarker
should distinguish specific disease states from nonspecific in-
flammation and injury.
Molecular genetics present some possibilities for insight
and innovation. For example, there are research groups usinggenotyping to study rare donor and recipient mismatches,
such as the homozygous loss of a protein in the recipient
only, which could lead to an immune response to the donor
organ. High-resolution tissue typing may be able to pre-
dict which mismatches are at high risk for triggering
destructive DSAs.
Tolerance research is based on the idea that the naturally
occurring negative regulatory mechanisms in the immune re-
sponse can be exploited to achieve graft survival free from
immunosuppressive drugs. The assumption is that early
interventions will provide durable, long-term changes in the
immune system that protect patients from TCMR and
AMR. However, TCMR and AMR are independently regu-
lated. TCMR is rare after 5 years, with virtually no cases
after 10 years posttransplant, apparently representing time-
dependent partial adaptive tolerance that precludes TCMR.
In contrast, AMR cases began to present approximately
1 year posttransplant and continued to present even 30 years
posttransplant.12 Tolerance initiatives need to take into ac-
count the separate regulation of AMR and TCMR and dem-
onstrate that the intervention can reliably prevent both, even
late AMR. Clinicians also need to reflect on some key issues
associated with conditioning protocols and cell injections in
tolerance studies, such as their safety and durability.
More information about the immunologic events and im-
mune regulation in the prevalent transplant population on
immunosuppression would be welcome and would synergize
with tolerance initiatives. What is the effect of immunosup-
pressive drugs on long-term adaptive changes and regulatory
circuits? Are many patients currently not at risk and receiving
more immunosuppression than they need? What phenotypes
represent nonadherence, and what phenotypes represent the
inherent failure of the current immunosuppressive drugs to
control late AMR?
Regenerativemedicine holds promise for reconditioning of
old organs and the generation of new ones. However, any so-
lutionsmust be robust, durable and able to competewith bio-
mechanical alternatives. There are also technical barriers to
consider, such as our limited ability to preserve organs on
normothermic ex vivo perfusion for prolonged periods, and
the inherent limitations in somatic cells, such as replicative se-
nescence, autophagy, mTOR mechanisms and other aging
mechanisms. We must also consider how regenerative medi-
cine strategies, dependent onmany cycles of cell division, will
impact the risk of oncogenesis and senescence.
In conclusion, the unmet needs in organ transplantation
present us with many opportunities for clinical innovation.
We have listed some, but there are many others. Transplanta-
tion has always been inspired by the dream that clinical inno-
vation can change patient outcomes, and that spirit must be
renewed if the next generation of challenges is to be met.Annual Review Clinic—and Other Models for the Future
MrMarc Clancy and Prof Alan Jardine
Posttransplant follow-up care is a series of consultations
through which we aim to maximize patient and graft sur-
vival, and quality of life. In the early period after transplanta-
tion, the focus is on prevention of rejection episodes and the
optimization of graft function. In the longer term, however,
we need to pay attention to the long-term risks of an other-
wise successful transplant, which include an increased risk
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ease. There is also a need to reinforce the need for life-long
adherence to medication. The purpose of this short review
is to highlight some issues and strategies to optimize long-
term treatment.
In Scotland, and elsewhere in theUS and Europe, there are 2
models for transplant follow-up: a “centralized”model and a
“repatriation”model. In the “centralized”model, patients re-
turn to the transplant center and are seen by dedicated trans-
plant specialists on an ongoing basis. In the “repatriation”
model, the transplant and early follow-up care is carried out
in the transplant center, and the patient is then “repatriated”
to their original referring unit for their follow-up care, usually
by nephrologists with more limited transplant expertise. The
East coast of Scotland uses the “repatriation”model and the
West coast uses the “centralized” model of care. The differ-
ence is driven largely by population demographics, and there
is similar variation in other regions of the world. For exam-
ple, Israni et al219 recently reported significant variation in
the structure and processes of postkidney transplant care in
the United States.
Data from the Scottish Renal Registry show a steep up-
ward trend in the number of patients with end-stage renal
failure, the majority of whom are now transplant recipients
(Figure 13).220 This is a pending capacity issue in terms of fu-
ture posttransplant follow-up, the potential shortage of ne-
phrologists with transplant experience, and the need to
design robust posttransplant follow-upmodels for the future.
An annual review clinic is one component of this
follow-up strategy. This involves a multidisciplinary assess-
ment to focus on factors that may not be a priority at routine
clinic visits. These include the identification andmanagement
of risk factors (eg, for cardiovascular disease, infection or
malignancy), and provision of health promotion advice and
support for both patients and relatives. It is part of a wider
strategy to promote patient engagement and empowerment,
and to improve adherence to treatment. There is no single
perfect model for posttransplant care, but there are numer-
ous national and international advisory guidelines.221,222
A typical structure for an annual review would involve skin
surveillance, most commonly by a dermatologist and involving
photography; a review of cardiovascular risk (fasting lipids, di-
abetes, blood pressure andmedications, such as statins); screen-
ing for diabetes (fasting glucose, HbA1c or glucose tolerance
test); and a discussion about adherence. For some patients,FIGURE 13. Maintenance renal replacement therapy trends inScotland.
APD, automated peritoneal dialysis; CAPD, continuous ambulatory
peritoneal dialysis; HD, hemodialysis. Reprinted from NHS National
Services Scotland. Scottish renal registry report. http://www.srr.
scot.nhs.uk/Publications/Main.html. ISD Scotland.advice, on diet andweight loss may be required, for others, spe-
cific issues, such as prepregnancy advice, may be needed.
Medicine has evolved froma traditional paternalisticmodel
to a more collaborative approach. Patients have ready access
to medical information and to their own clinical data. The
clinical consultation is also more bi-directional than in the
past. In the US, there is an online portal, Renal Patient View
(www.patientview.org), where patients can view their results,
medications, and letters sent about them to other health care
professionals. Patients can also enter blood pressure, glucose
and weight measurements taken at home. Renal Patient View
has been adopted by many clinics and patients, and its uptake
has been rapid and extensive. EgtonMedical Information Sys-
tems (https://patient.emisaccess.co.uk. Accessed 15March 2016)
is another system accessible by patients that is widely used across
primary health care in the US. These web-based systems, acces-
sible through a variety of platforms—including smartphones—
give patients ownership of their own care and dynamic access
to laboratory data. The use of such technology allows us to
monitor patients remotely, in real-time, in a way that was
previously unthinkable, while empowering patients to take
a much more active role in their own management with re-
spect to both adherence and risk-factor management.
There are tools that have been developed to help identify
patients at risk of poor long-term outcomes, including a ‘car-
diovascular risk calculator’ for renal transplant recipients.98
This calculator enables quick estimation of a patient’s cardio-
vascular risk in the clinic, and estimates the potential benefit
of, for example, weight loss or lipid lowering therapy.98 An-
other tool is the ‘risk factor calculator’ app (Astellas Pharma
Europe Ltd). This app enables assessment of adherence using
the validated BAASIS questionnaire,223 evolution of renal
function by linear regression, using previously collected
eGFR (MDRD), and estimation of intrapatient variability
of tacrolimus exposure. The use of this type of calculator
with the patient can help explain the importance of risk
management and is likely to be an emerging technology
for the future.
The rate at which the posttransplant population is grow-
ing is not being reflected in the resources available to manage
these patients, suggesting that capacity may become an issue
within clinics in the future. Moving some monitoring of pa-
tient parameters outside of the conventional clinical setting
may be a viable option. A number of remote patient monitor-
ing and telehealth devices are already in use, where measure-
ments, for example, blood pressure, hemoglobin, glucose,
HbA1c and pill taking, and so on, can be captured at home
and automatically transmitted back to the clinic. Telemedi-
cine is being piloted in transplantation follow up to monitor
nonadherence to treatment.224
Aswe develop strategies for the future, we need to focus on
the management and risk of the emerging complications—
especially cancer and cardiovascular disease—and the risks
of complacency and nonadherence. An annual review clinic
with amultidisciplinary team to assess cardiovascular risk, di-
abetes, dermatology (skin surveillance for malignancies), car-
diology, medication adherence, graft surveillance and
biopsy—clinical measurements beyond the typical simple
consultation—is one strategy. Similarly, technological ad-
vances may allow us to empower and educate patients, and
even monitor them remotely, to improve long-term graft and
patient outcomes without overburdening clinical services.
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Prof Edward K Geissler
Preventing immunologic rejection of transplanted organs
without the need for long-term use of pharmacological immu-
nosuppression is a primary objective in transplantation medi-
cine. Reducing this need would dramatically improve the
outcome for transplant recipients and would reduce health
care costs. A reliable means of achieving this goal has not been
realized with pharmacologic or biologic agents, so we must
now look to new, innovative approaches. With this objective,
The ONE Study consortium of European Union-led investiga-
tors and colleagues from the United States are applying the
concept of cell therapy to human kidney transplantation.
Conditioning the immune response of transplant recipients
toward allograft acceptance, using advanced, cell-based me-
dicinal products, is a promising therapeutic approach, and
is now becoming technically feasible. There are various alter-
native tolerance-promoting cell types, including regulatory
T cells, macrophages and dendritic cells, which are now at
a state of development that allows them to be trialled in
early-stage clinical studies. The central focus of The ONE
Study is to produce distinct populations of hematopoietic
regulatory cells and, simultaneously, comparatively test their
safety and promise in minimizing pharmacologic immuno-
suppression in organ transplantation.
To assess this, several regulatory cell products are being
tested in a coordinated group of clinical trials through The
ONE Study; they have been licensed over the past few years
for production according to stringent manufacturing practice
conditions. By directly evaluating the various immunoregula-
tory cell therapies against one another in this way, and also
against a group of patients not receiving cell therapy (Refer-
ence Group Trial), The ONE Study is expected to determine
whether further testing of each cell product in clinical trials
is warranted. We have chosen to include in The ONE Study
those cell preparations that, in our view, represent the most
promising therapeutic agents, and which are ready for
clinical application: M regs (Regensburg); polyclonal Tregs
(Charité, Berlin, and King’s College London and the Uni-
versity of Oxford); donor-antigen-reactive Tregs (the Univer-
sity of California, San Francisco); donor alloanergized Tregs
(Massachusetts General Hospital, Harvard University,
Boston); Tr1 cells (Fondazione Centro San Raffaele, Milan);
and tolerogenic dendritic cells (CHU de Nantes).
During the first period of the project, the main activity of
the clinical centers involved in The ONE Study has been the
preparation of the clinical protocols for the Reference Group
Trial and the submission of an IMPD (Investigational Medic-
inal Product Dossier) or IND (Investigational New Drug) to
the regulatory agencies for the Cell Therapy Trials, as well
as the development of a centralized immune monitoring pro-
gram. The Reference Group Trial (www.clinicaltrials.gov) is
being conducted at all of the sites mentioned above, and
serves as an independent, multi-center, phase IV clinical trial
that is designed to corroborate historic renal transplantation
statistics and generate ‘baseline’ immunologic health-related
quality of life, and health-economic data sets for The ONE
Study cell therapy trials. The Reference Group Trial uses a
standard immunosuppressive treatment regimen that is simi-
lar to the one that is being used in the Cell Therapy Trials.
The Reference Group Trial has finished recruitment, andhas now entered the follow-up phase. In parallel, 6 Cell Ther-
apy Trials have begun and will continue to recruit patients,
the goal being to recruit 8 to 16 patients into each trial. All
of the groups conducting Cell Therapy Trials will essentially
follow the same immunosuppressive treatment regimen, with
the exception that their specific cell therapy products will be
applied to the kidney transplant recipients; cell infusion re-
places basiliximab induction therapy being used in the Refer-
ence Group Trial. With The ONE Study concept, it will be
possible to compare the results of each cell therapy trial to each
other, as well as with the results from patients receiving stan-
dard therapy in the Reference Group Trial.
One of the objectives of theONE Study is to standardize im-
mune monitoring of transplant recipients, so that a true and
fair comparison of results can be made between the individual
cell therapy trials, as well as between those trials and the Ref-
erence Group Trial. The ONE Study immune monitoring
concept involves using strict standardized sample collection
and testing (eg, flow cytometry, polymerase chain reaction,
and so on). Testing is performed centrally at the Charité
(Berlin) to ensure that the test results from all samples col-
lected in the different trials, and at the different sites, can
be reliably and meaningfully compared. The immune mon-
itoring has already been fully developed and implemented in
the Reference Group Trial, demonstrating the feasibility and
value of this testing concept. For instance, TheONE Study flow
cytometry panels have been developed and standardized with
a third party (Beckman Coulter).225 The concept of The ONE
Study immune monitoring has generated significant interest
and is presently being adopted by other international immune
monitoring laboratories as a means of standardizing immune
monitoring performance.226 Standardized electronic data
collection systems have also been developed in parallel to en-
sure consistent data gathering. This conceptual approach
to immune monitoring is a major accomplishment of The
ONE Study.
In summary, theONEStudy is progressingwell toward the
planned objectives. The Reference Group Trial, to which the
Cell Therapy Trials will be compared, has completed recruit-
ment. Moreover, 6 Cell Therapy Trials have begun and re-
main in the recruitment phase. Supporting these studies,
our novel immune monitoring program has been fully devel-
oped, standardized and implemented successfully in this lo-
gistically challenging international study, providing a
conceptual framework for other clinical trials that could ben-
efit from precise monitoring of immunologic therapies. The
ONE Study is well underway and is expected to yield useful
information regarding the potential for cell therapy in kidney
transplantation as a means of reducing the need for conven-
tional immunosuppressive drugs.Clinical Innovation in Transplantation
Dr Alejandro Soto-Gutiérrez
End-stage liver disease is responsible for over 30000
deaths annually in the United States alone.227,228 Medical
therapy can prolong life, but the only definitive therapy for
severe cases of end-stage liver disease is allogeneic liver
transplantation—either a partial liver from a living-related
donor or a whole deceased-donor liver. The success of liver
transplantation has evolved in many ways, and indications
for this therapeutic modality have expanded to include many
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metabolic diseases, and some cancers.229,230 Yet, the pool
of donor livers fails to keep pace with the growing demand.
Based on the US OPTN registry data (https://optn.trans-
plant.hrsa.gov/), as of 10 July 2015, there were 15 751 people
on the liver waiting list in 2014, and only 6729 of these re-
ceived a transplant. In addition to this, there is also an expec-
tation that the donor pool will shrink further due to the
obesity epidemic. The use of donor livers with greater than
30% liver steatosis is increasingly common in transplanta-
tion, the presence of which is a significant risk factor for in-
creased primary nonfunction and initial poor graft function
in liver transplantation.231 These data point to one fact: or-
gan availability is an absolute constraint on the number of liver
transplants that can be performed. Thus, creation and univer-
sal availability of a liver graft from autologous tissue and cells
(eg, induced pluripotent-derived liver cells) would dramatically
change this equation by increasing the number of organs avail-
able for transplantation, and eliminating the need for life-long
immunosuppression and its accompanying complications.
The ongoing shortage of available organs has led investi-
gations toward innovative transplant techniques, including
efforts to produce implantable grafts without the need for
an organ donor. A popular strategy being developed for
the creation of such implantable liver grafts involves the
decellularization of whole organs, and subsequent reseeding
with relevant cell types, followed by maturation of the neo-
organ in a physiologically appropriate bioreactor, and then
implantation of these constructs in animals.232-240 Although
most studies using this approach have demonstrated feasibil-
ity, they have also demonstrated limited survivability and
function of the grafts after implantation into animals. These
disappointing results have been largely attributed to a failure
to maintain a durable vascular network and failure to rebuild
the complex liver microarchitecture required for function by
the assembled liver graft after transplantation. Currently, the
major challenge with regard to the success of transplantable
bioengineered liver grafts is the development of durable vascu-
lar networks. Any incompletely reendothelialized vasculature
is at risk for acute thrombosis, leading to localized organ fail-
ure. Therefore, ideally, complete vascular endothelializa-
tion is desirable for clinical applications; however, new
nonthrombogenic biomaterial technologies could provide
a useful alternative.241,242
With regard to the development of autologous liver grafts,
the identification of an abundant source of human cells is a
major limitation to the clinical application of bioengineered
organs for transplantation. To date, induced pluripotent
stem cells (iPSCs) represent a potential source for liver tissue
creation. Nevertheless, complete reestablishment of the liver
microarchitecture would require incorporation of liver
nonparenchymal cells (eg, bile duct cells, sinusoidal endothe-
lial cells, stellate cells, and so on), necessitating iPSC differen-
tiation for these cell types. Additionally, differentiated cells
derived from iPSCs may still be immature, functionally re-
sembling fetal or neonatal phenotypes. Thus, cell maturity
may prove to be critical for diseases requiring functional dif-
ferentiated cells. In some instances of end-stage liver disease,
and for inborn errors of liver metabolism, an entire liver may
not be required and auxiliary partial liver transplantation has
been suggested as a therapeutic option,243 although a graft
representing at least 35% of a liver would be necessary.Another major challenge in the field of liver engineering
will be to design protocols for massive cell engraftment to
fulfil the necessary liver mass for transplantation. Organ-
engineering technology is in its infancy and will need to over-
come countless translational hurdles before liver grafts can be
used widely in preclinical studies. However, most elements of
the technology, although not yet validated by a reproducible
protocol, are in place. Critical aspects of the developmental
biology of the liver remain unknown, but the manufacture
of replacement organs is no longer science fiction and re-
mains a promising area for investigation.Technological Innovation in Transplantation
Prof Christophe Mariat
There are a number of limitations facing the transplanta-
tion community; however, identifying these inadequacies en-
ables us to translate limitations into innovations, leading to
improved outcomes for our patients. The phenomenon of
the emergence of DSAs, and the central role played by hu-
moral immunity in the process of graft failure, led to the in-
troduction of Luminex-based antibody screening technology
into clinical practice, which has revolutionized diagnostic
procedures in transplantation and has led to a greater under-
standing of the causes of graft failure. Many other technolo-
gies are also being developed and are set to further improve
the way we diagnose and treat our patients; however, these
technologies are currently in their infancy and are not yet
available for routine clinical practice. The development of in-
novations that were not necessarily originally focused on
health care, including mobile applications, are also under
way to facilitate, and in some cases improve, the interaction
between patients and their physicians. These innovations in-
clude the ingestible sensor system (ISS), a care/monitoring ap-
plication, and a microsampling device.
The ISS is being developed to accurately track patients’
adherence to treatment by the ingestion of microsensors
with, or included in, the oral dosage form of drugs.244 This
system has already been introduced in Europe and the
United States.244 The ISS consists of an ingestible event
marker (IEM), the microsensor that becomes activated after
ingestion, and an adhesive personal monitor patch to detect
the IEM once activated. Using wireless Bluetooth-based
technology, the adhesive personal monitor can relay infor-
mation to a smartphone, which in turn sends the data to a se-
cured, centralized data storage and processing location.
Although this “Big Brother” style approachmay seem daunt-
ing, the system has been associated with high (99.4%) adher-
ence to mycophenolate in kidney transplantation,244 and
similar innovations are already being used in various fields
of medicine. As adherence to treatment is particularly impor-
tant in transplantation, these innovative techniques could
help improve long-term outcomes for our patients.
The patient care/monitoring application is being devel-
oped to help manage and provide appropriate care for the
growing number of transplant outpatients. Such patients typ-
ically only attend an annual hospital consultation; however,
between these yearly visits they must also undergo routine bi-
ologic check-ups in a laboratory closer to their home. This
means that the laboratory must send the information to the
physician, who must then compare results with the patient’s
medical chart review to make an accurate analysis. This
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duction of a care/monitoring application could help improve
the efficiency of this process and could easily be implemented
in the clinic. The patient can download the application to
their smartphone, enter the value of their test results in the
application themselves, and send messages to the physician.
In turn, the physician will receive these results on his/her
computer. A “flag” appears on the physician’s interface for
any patient who has results outside the normal range that
has been specifically set for that patient. The physician can
then assess the reasons for the red flag and implement the ap-
propriate action. For transplant patients, this innovation can
be used to monitor variables, such as serum creatinine levels,
hemoglobin concentrations, leukocyte counts, and trough
levels of immunosuppressive drugs.
This type of patient monitoring system is currently being
implemented in several centers, including the Nephrology,
Dialysis and Renal Transplantation Center at Jean Monnet
University. So far, 50 patients have used this system and the
feedback has been positive, with patients frequently comment-
ing that they feel safer using this type of technology to
measure their health status. One drawback, however, is
the overutilization of the text messaging option, with phy-
sicians being inundated with questions that would ordinarily
be addressed by a general practitioner. Further assessment
of the system on a larger scale is warranted to determine
its impact on the physicians’ workloads and on patients’
treatment outcomes.
The third type of innovation in development is a mi-
crosampling device to help with therapeutic drug monitoring
in transplant outpatients. There are several certified immuno-
assays that can be used for therapeutic drug monitoring, de-
pending on the laboratory used. As a result, variability is
observed between readings from 1 laboratory versus another
(for example between external and central laboratories), based
on the assay used. When comparing results between centers
this should, therefore, be taken into account.245,246 The intro-
duction of a microsampling device could help circumvent this
issue: a patient, with the assistance of a nurse, if required, can
collect samples at home using a ready-to-use chip and forward
them to the laboratory for analysis. This is similar to available
methods for monitoring blood glucose concentrations in pa-
tients with diabetes. With such a system, therapeutic drug
monitoring could be performed using a single drop of blood,
which could be sent for analysis at a central laboratory. Initial
validation of the system for tacrolimus measurements have
shown promising results in our clinic, with strong correlations
between tacrolimus concentration readings from the device
and readings from traditional blood samples. Further analytic
and clinical validation of the system is required before it can be
introduced into routine clinical practice.
In conclusion, various technologies and innovations to
improve outcomes for transplant patients are currently in
development. A major focus is on applications to improve
adherence to medication, although there is limited informa-
tion regarding the impact of such applications on clinical
outcomes. A primary concern with the advent of such appli-
cations is the ability to maintain patients' privacy, parti-
cularly if applications are somehow connected to social
networking sites. In addition, it is important that such inno-
vations are tailored to meet the needs of both patient and
physician, and that both adapt their routines or habits toensure that the introduction of these novel technologies is ef-
fective and beneficial to both parties.
Transforming Health Care: the Patient and the App
MrMonty Metzger
The evidence of the past is all around us and information
we create immediately becomes history. The past provides a
great resource of knowledge, and human nature generally
results in a backward-looking society. Perhaps only now
we are beginning to understand how this past information
can help us to create an understanding of what the future
might hold. The story of the patient and the app illustrates
how digitalization is shaping the evolution of the health
care industry.
The future of health care is fast approaching: a future
where, instead of coming in for routine check-ups, your pa-
tients’ clinical indicators will be collected using wearable
technologies, sent securely to your clinic, and video consulta-
tions will be used to discuss their recent readings. A future
where completemedical records and histories will flow seam-
lessly between the relevant members of the collaborative
health care team and results will be displayed in context with
the wider patient population. The demands on the health
care system have been getting incrementally larger and
change, although daunting, is essential. Glimmers of this
change are starting to appear.
Digitalization advantageously combines 4 unique factors:
(1) a global talent and knowledge-sharing community where
patients and experts collaborate online, and can all benefit
from virtually inexhaustible resources; (2) low production
costs—a smart team can often develop a digital product in
only a few hours; (3) lean technology—innovation through trial
and error rather than attempting to produce a 100% perfect
product the first time around; and (4) new access to capital—
for example, funding available through potential patients or
“crowdfunding,” where products that have not even been pro-
duced or introduced can be funded by their target audience.
There are indications that these 4 elements are coming to-
gether to address health care issues. Venture capitalists from
Silicon Valley and New York invested over 6 billion US dol-
lars in health technologies in 2015. The fact that many were
start-up companies implies that a significant paradigm shift
toward technological development has occurred.
Whether it is a revolution led by Twitter or transportation
services like Uber, digital influences are shaping all industries.
Within health care, we are experiencing a dramatic change in
the way we produce and consume data. The smartphone in
particular liberates and empowers us to a new degree; for dig-
italized health care and medicine, it is the biggest moment of
opportunity in our lifetimes. The digitalization of routine
medicine will allow patients to shop by price, convenience
and reputation, and to benefit from a greater number of op-
tions. What does this mean for physicians and how will the
health care community evolve to continue to communicate
with the digitally empowered patient? As we transition
toward the doctorless patient and virtual clinic visits/
consultations, a 40% reduction in doctors' visits resulting
from “virtual visits” represents a 60 billion dollar market op-
portunity in the United States alone.
The empowered patient can be armed with substantial
knowledge about their lifestyle and conditions. For a 200
US dollar price tag, one can already purchase a number of
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an iPhone tomeasure metrics such as blood pressure, electro-
cardiography data, blood oxygen, temperature and lung
function; Scanadu Scout is a similar crowdfunded project.
One can obtain an interactive pregnancy tracking device to
track heart rate or fetal rollovers, or a ‘23andMe’ kit that
provides considerable amounts of genetic data.
Empowered patients typically participate in social commu-
nities to gather advice or self-diagnose before medical inter-
vention. They take a central role in determining when they
interact with the health care system and how their care is de-
livered. They are better prepared to collaborate with their
doctors on the best course of action, and help implement
treatment plans to ensure optimal outcomes. Advanced
learning centers and the development of algorithms are pro-
viding more information about these patients. This informa-
tion is used to assist the patient to make healthier lifestyle
decisions, but the potential to pair the data with gaming me-
chanics could also help to provide services to insurance com-
panies, for example. The net result of this approach may be a
healthier population that is less reliant on the resources pro-
vided by the broader health care system.
Wherever we are, our smartphones and personal devices
provide us with abundant information. Many tools, such as
Fitbit and Jawbone, exist to allow an individual to measure
vital signs and fitness data, and there are global online
wellbeing communities, such as Quantified Self, which
promotes itself using the slogan ‘self-knowledge through
numbers’. Within the hospital environment too, there is
a trend toward ubiquitous information. Philips are cur-
rently exploring the potential of Google Glass to allow
doctors to acquire critical information about their patients
in a hands-free format.
With many of the new technologies, the challenge is really
how to use and visualize the data collected, a fact that also
pertains to many big data projects that are frequently being
undertaken in medicine. For example, projects that use sen-
sors within contact lenses to measure glucose metrics, or
those using ingested sensors to monitor internal factors have
constant data streams to be processed. These remotemethods
of data collection are also reshaping the relationship that has
traditionally defined health care: the relationship between the
patient and the doctor.
In essence, our ability to successfully orchestrate the infor-
mation from our past with the real-time data that we are
collecting today could culminate in predictive technology
that can give us better insights into our future. One thing in
our future is certain already, though: everything in the future
that can be digitalized will be digitalized, and the rest will be
as well.FIGURE 14. The variation in prostate-specific antigen testing in dif-
ferent populations. Shading represents the quintiles, to encourage
the jurisdictions to think about overuse or underuse of diagnostic ser-
vices, if they appear in the top or bottom quintile. PCT, primary care
trust. Reprinted from NHS England. The NHS Atlas of Variation in Di-
agnostic Services. Reducing Unwarranted Variation to Increase Value
and Improve Quality. November 2013.Thinking Big: “Big Data” and the Future of Health Care
Sir Muir Gray
Health care has made an astonishing impact on the health
of populations and individuals in the last 50 years, and trans-
plantation has been an example of the way in which high-
tech science has been translated into effective care. This has
been the second revolution in health care—the first being
the Public Health Revolution of the 19th century. However,
at the end of 50 years of astonishing progress, a number of
problems can be seen in every country and these wererevealed by the unwarranted variations that are a striking
feature of health care.
Unwarranted variations were defined by John Wennberg,
who published the first Atlas of Health care (available at:
http://www.dartmouthatlas.org/. Accessed 15 March 2016)
fromDartmouth University, as variations that cannot be ex-
plained by either variation in need or variation in prefer-
ence.247 With the exception of trauma, and to a lesser
extent cancer, unwarranted variation can be observed in every
clinical specialty in conditions where only the people who are
affected reach the specialized services. An example of this, the
variation in prostate-specific antigen testing in different popu-
lations, is shown in Figure 14.
The unwarranted variation reveals other problems.
• Failure to prevent disease and disability (for example, fail-
ure to prevent stroke among people with atrial fibrillation)
• Waste of resources
• Inequity (under provision of services to some groups)
• Overuse and harm resulting fromwhat the BMJ has called
“TooMuchMedicine” (available at: http://www.bmj.com/
too-much-medicine. Accessed 15 March 2016)
All of these have been revealed by big data.
Big Data
The term “big data” is so widely used that it requires def-
inition and there are, of course, many definitions. In this pa-
per we are using “big data” to refer to the management of
health data in what might be called ‘cloud computing’ rather
than mainframe computing. For years we have struggled to
connect different mainframes, but now the internet has
changed that and allows us to relate data much more easily.
The consequence of this has been a shift from a focus on in-
stitutional quality to a focus on value.
Quality and Value
It is vitally important to improve the quality and safety of
care, and transplant services have demonstrated this excel-
lently. However, quality is different from value and there
are 3 aspects of value set out below:
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to different subgroups in the population
• Technical value, determined by how well resources are
used for all the people in need in the population
• Personalized value, determined by how well decisions re-
late to the values of each individual
The technical quality of transplant services is high, based
on registries, but in thinking about the future for both kidney
and liver transplantation we need to think about 2 other as-
pects that are interlinked: allocative and personal aspects
of value.FIGURE 15. Diagrammatical representation of resource investment
as a relationship to the benefit/harm ratio. Figure adapted with per-
mission from Gray JA. Tools for Transformation: Essential Glossary
for Understanding Value and Efficiency in Health and Healthcare.
3rd ed. BVHC; 2014. Adaptations are themselves works protected
by copyright. So in order to publish this adaptation, authorization
must be obtained both from the owner of the copyright in the original
work and from the owner of copyright in the translation or adaptation.Allocative Value and Transplantation
Over the last 30 years, investment in health services has in-
creased steadily, but, partly as a consequence of the global fi-
nancial collapse, the growth is stopping inmany countries. In
the countries in which it is continuing, the gap between need
and demand on the one hand and resources on the other, will
place intense pressure on budgets. Furthermore, need is in-
creasing in both kidney and liver disease, with the latter pre-
senting a number of big challenges. Obviously, a case could
be made for increased liver transplantation, but the increase
in obesity and HCV also demand attention and resources.
This means that within each of these conditions choices have
to be made.
Within liver disease, the choices include:
• Increased investment in HCV prevention
• Increased investment in HCV treatment
• Increased investment in the prevention of obesity
• Increased investment in prevention of alcohol misuse
• Increased investment in end-stage liver failure and
transplantation
These choices have never been starkly presented before,
but are now the focus of a major research effort in Oxford,
based at the Institute for Value-based Health Care. For kid-
ney disease, the choices are between the different modalities
of managing kidney disease—prevention, treatment, dialysis
and transplantation—and it may be that resources need to
be switched from dialysis to transplantation to take into ac-
count personalized value.Personalized Value
Decisions made by individuals relate obviously to the evi-
dence, but that evidence has to be tailored to their particular
clinical condition by the clinician. The third factor in a deci-
sion is their values. Personalized Value and Value for Popula-
tions, both allocative and technical, are interwoven. At a
population level there is great concern about what Avedis
Donabedian proposed in 1980 as care beyond the point of
optimality, illustrated in Figure 15. In this figure, it can be
seen that investment reaches a point at which the balance of
benefit to harm is not suitable for society249; antibiotic pre-
scribing is a classic example of this. However, there is grow-
ing concern about people receiving inappropriate dialysis
when they have multiple conditions. It may be that if choices
were put to individuals with a number of comorbidities they
would choose not to have dialysis, thus freeing up resources,
which can be switched to transplantation.Resource Stewardship
These are issues not for payers to consider directly, but for cli-
nician and patient groups to discuss and debate. Furthermore,
the right balance between different interventions for liver
and kidney disease will differ from 1 population to another
depending on the past investment decisions. These have
rarely been explicit and have led to the current position in
which there is a high rate of variation.
Publication of an Atlas of Organ and Transplantation is
being planned by Public Health England and it will undoubt-
edly reveal not only wide variation, but alsomany opportuni-
ties for increasing value. Big data makes this possible and
relatively easy for the first time.
SUMMARY OF KEY LEARNINGS
Associate Prof JonasWadström and Prof Bo-Göran Ericzon
The face of health care is continuously evolving andwe are
now on the brink of a new era of digitalizedmedicine.Mobile
applications, such as ingestible sensor systems and patient
monitoring applications are set to enter the field of transplan-
tation. New technologies can facilitate personalization and
will hopefully help us to further improve the management
of transplant patients.
As we attempt to reduce the disparity between organ avail-
ability and patients awaiting transplant, we are transplanting
organs from a greater number of marginal donors. Concur-
rently, advances are being made in donor management before
procurement, as well as new technological advances in organ
storage and reperfusion. Although a number of these advance-
ments are not yet widely available, they yield promising results
that could bring advances in solid organ transplantation.
Advances in transplantation, however, are not restricted to
technological innovations and donormanagement.Our under-
standing of the field has been enhanced and is changing the
way we treat our patients. Over the past decade, an important
milestone in improving long-term outcomes has been to better
understand the modifiable risk factors for graft loss. We need
to look beyond the ‘traditional’ risk factors of age and hyper-
tension during the management of our patients and recognize
that underimmunosuppression or overimmunosuppression,
poor adherence to therapy, and high variability of CNI expo-
sure are important aspects that need to be monitored and
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graft survival posttransplant, we must also recognize the im-
pact that cardiovascular disease has on the survival of trans-
plant recipients and take steps to modify the associated risks.
With these risk factors in mind, a key unmet need currently
facing the transplant community is the requirement to im-
prove long-term transplant management in an era where
there are few new phase II and III clinical trials. To achieve
this, it is necessary to use new data sources to classify patients
accurately and then to confirm those patients ‘at risk’ of poor
outcomes at the individual patient level. These data assess-
ments could lead to future tests, interventions and clinical
trials. For these reasons, we are looking beyond RCTs in
transplantation and using registries to give us an indication
of patterns in long-term outcomes.
Summary of Key Learnings in Kidney Transplantation
Associate Prof Jonas Wadström
In light of the use of marginal donors in kidney transplanta-
tion, new techniques are required to optimize donor manage-
ment, improve organ preservation after retrieval and attenuate
reperfusion to improve graft survival. However, there is a gap
in the literature between experimental research addressing IRI
and data that can be translated to clinical practice.43 It is clear
that to improve graft and patient survival, donor management
strategies need to be used within the context of patient manage-
ment and alongside pharmacologic therapies.
CNI minimization, with the aim of reducing nephrotoxi-
city, was traditionally common practice in kidney transplan-
tation; however, data suggest that underimmunosuppression
has a negative impact on graft survival.25,78 Registry data
show that tacrolimus trough levels less than 5 ng/mL 1 year
posttransplant are associated with inferior graft survival,
indicating that low tacrolimus trough levels should be
avoided.25 Steps need to be taken to modify the risk factors
associated with underimmunosuppression, including im-
proving adherence to treatment and minimizing the variabil-
ity of CNI exposure to improve long-term outcomes.
Data suggest that DSA now supersede CNI toxicity and
chronic allograft nephropathy in their ability to cause chronic
deterioration of the transplanted graft.50 Information to as-
sist us in understanding the intricate nature of the histologic
patterns that can be indicative of subclinical AMR and kid-
ney graft failure is emerging.54 The implementation of effec-
tive screening procedures and improved kidney allocation
policies in our clinics will enable us to move to prevent rather
than treat AMR and to improve therapeutic outcomes. The
development of DSA and, subsequently, the emergence of
AMR posttransplant have been associated with nonadher-
ence to treatment.
Nonadherence is widespread in the transplant community.
Addressing issues associated with nonadherence remains a
key challenge in transplantation, in part, due to the difficulty
in assessing its prevalence, as there is currently no ‘gold stan-
dard’ for use in routine clinical practice. Innovative technolo-
gies have the potential to assist us in improving adherence
and outcomes for our patients.244,250 However, these tech-
nologies are not yet widely available in clinical practice.
Nonadherence to treatment has been associated with high
intrapatient variability of exposure, both of which can lead to
poor long-term outcomes.30,31,57,58 High intrapatient vari-
ability of tacrolimus exposure defines a group of patientsproven to manifest rejection, graft failure and dysfunction
at a higher rate than the lower variability population. Al-
though it is widely accepted that graft and patient survival
can be affected by CNI trough levels falling vastly outside
of the target range, the clinical impact on patients with small
fluctuations outside of the therapeutic range also appears to
be important. Interventions to reduce variability would,
therefore, seem justified and sensible.
In order to identify patientswho are at risk of nonadherence
to treatment and high intrapatient variability, we need to in-
corporate routine monitoring of these risk factors into clinical
practice. Only by identifying patients who are at risk early
posttransplant and monitoring risk over time can we adjust
immunosuppressive regimens and patient care to meet in-
dividual needs. Using new digital innovations, such as mo-
bile apps and ingestible sensors, has the potential to assist
us with this task without increasing the burden on our
health care systems.
As long-term graft survival increases, we need to look to-
ward the risk factors associated with cardiovascular disease
to further improve survival in kidney transplant recipients. In-
terestingly, in a study of over a million adults (nontransplant),
a decline in renal function was associated with an increased risk
of the occurrence of cardiovascular events.94 Cardiovascular
risk factors should be managed both pretransplant and
posttransplant and it is important to recognize the impact of
the choice of immunosuppressive regimen on cardiovascular
risk. As such, immunosuppression should be chosen and
amended in accordance with each patient’s clinical profile.
Risk factor equations, with appropriate validation, could
provide insights into the long-term potential of different
treatment regimens and provide useful tools for individual
patient counselling.98
As health care needs change,we should explore and embrace
new technologies for patient monitoring and communication.
By using technology to promote patient engagement and pro-
vide tools to enable patient empowerment, we can begin to im-
plement these changes and to improve long-term outcomes for
our patients.
Key learnings in kidney transplantation
• Information to assist us in understanding the intricate na-
ture of the histologic patterns that can be indicative of
subclinical AMR and kidney graft failure is emerging
• Nonadherence is widespread in the transplant commu-
nity and this remains a key challenge
• High intrapatient variability of CNI exposure defines a
group of patients who will manifest rejection, graft fail-
ure and dysfunction at a higher rate than the lower
variability population
• Underimmunosuppression increases the development of
DSA andAMRand has a negative impact on graft survival
• As long-term graft survival increases, we need to look to-
ward the risk factors associatedwith cardiovascular disease
to further improve survival in kidney transplant recipients
• By identifying “at risk” patients and modifying the risk
factors for poor graft survival, we could achieve better
outcomes for our patients in the long term
• As health care needs change, we should explore and em-
brace new technologies for patient monitoring and com-
munication. By using these technologies to promote
patient engagement and provide tools to enable patient
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and to improve long-term outcomes for our patients
Summary of Key Learnings in Liver Transplantation
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The most commonly used immunosuppressive regimen in
liver transplantation consists of tacrolimus in combination
with MMF, with or without steroids. Five years ago, a study
was published confirming the noninferiority of efficacy with
prolonged-release versus immediate-release tacrolimus,166 and
since then, there has been evidence to suggest that prolonged-
release tacrolimus is associated with graft- and patient-survival
benefits for liver transplant patients compared with the
immediate-release formulation.18 The reasons for the potential
improvements in survival with prolonged-release tacrolimus are
yet to be fully understood; however, we theorize that by using
prolonged-release tacrolimus in liver transplantation, we are
modifying a number of risk factors for poor graft survival, which
play an important role in improving outcomes for our patients.
Risk factors, such as early allograft dysfunction and bili-
ary strictures, remain a major cause of inferior outcomes in
liver transplantation, and new techniques are required to
prevent their occurrence.122 In addition to advances in per-
fusion strategies, delaying organ procurement after brain
death, using steroid therapy in deceased donors and using
N-acetylcysteine before and during procurement warrant
further investigation. By preventing organ damage, we can
improve the results of liver transplantation and widen its ap-
plication by increasing the pool of organs suitable for trans-
plantation. Some strategies are already available and should
become the standard of care for our patients; some are in
development, but it is important that multiple strategies
targeting multiple mechanisms are applied at each step of
the transplantation process.
Pretransplant and posttransplant DSA formation presents
a further challenge for improving long-term outcomes in liver
transplantation. Our understanding of the impact of DSAs,
and acute and chronic AMR, is still evolving. The occurrence
of de novo DSA in liver transplantation is low; however, its
occurrence is associated with double the risk of death.4 This
presents a particular challenge for the screening of patients for
de novo DSA, making the most cost-effective approach to
improving outcomes not only through testing but also through
prevention. In the future, utilization of biomarkers will aid
us with identification of patients at risk of de novo DSA for-
mation and injury, and thereby guide us with regard to appro-
priate immunosuppression minimization.
The concept of tacrolimus minimization as a protective
factor in liver transplantation is only partly based on evi-
dence or data from RCTs in liver transplantation, but also
seemingly on traditional views of CNI-related side effects
(predominantly on kidney function and posttransplant lym-
phoproliferative disorder). It is important to achieve the right
level of tacrolimus exposure both early posttransplant and
during maintenance therapy, as underexposure has been
linked with reduced graft survival and patient outcomes169
and overimmunosuppression can also lead to poorer out-
comes. Variability of tacrolimus exposure posttransplant is
well established, but its implications for liver transplant re-
cipients are less well characterized than for kidney transplantrecipients, even though high variability of tacrolimus expo-
sure has been associated with late allograft rejection after
liver transplantation.163,164
High intrapatient variability of tacrolimus exposure has
also been associated with nonadherence to treatment.251 It
is important to recognize that the immunosuppression regi-
men is not only specific for the drug dose, targeted to
predefined trough levels, but also for the intervals between
doses. Clinicians are probably naïve in their expectation of
their patients’ ability to comply with treatment regimens;
nonadherence is more prevalent than assumed.60 Perhaps
emerging innovative technologies will assist us in reducing
nonadherence in our patients. ACR is themost obvious conse-
quence of nonadherence, with late acute episodes being more
difficult to treat. These issues are deserving of further study,
but in the meantime it seems prudent to advocate stable im-
munosuppression strategies as the most effective protection.
Cardiovascular events are one of the most important
causes of morbidity and mortality postliver transplant. In
pretransplant patients, attention should focus on identifying
subclinical cardiac events, as well as screening for and
treating portopulmonary hypertension and CAD. Lifestyle
modification is the first approach to reducing cardiovascular
risk; however, when these are proven to be ineffective, mod-
ification of the immunosuppressive regimen and specific
medication should be considered. It is the choice of immuno-
suppressive therapy, both early posttransplant and in the
long term, that still represents the most important factor
influencing the posttransplant cardiovascular complications
in the transplanted patient.
Through greater understanding and advances in trans-
plantation, patients with functioning grafts are living longer,
increasing the need to use health care resources more effi-
ciently. We should learn from other therapy areas, such as di-
abetes, how to use new patient-orientated technologies to
improve patient–physician interactions. Exploring such inno-
vations for transplantation could enhance patient engagement,
communication and treatment monitoring, and potentially
translate into improvements in long-term outcomes.Key learnings in liver transplantation
• Five years ago, non-inferiority of efficacy for prolonged-
release versus immediate-release tacrolimuswas reported;
since then, there has been evidence to suggest that
prolonged-release tacrolimus is associated with graft-
and patient-survival benefits for liver transplant patients
compared with the immediate-release formulation
• Early adequate immunosuppression seems necessary for
optimal immunologic outcomes, especially in light of
the role of de novo DSAs and the association between
DSAs, AMR and graft loss
• High intrapatient variability of tacrolimus exposure has
been associated with late allograft rejection
• ACR is the most obvious consequence of non-adherence
to treatment, with late acute episodes being more difficult
to treat
• Cardiovascular events are one of the most important
causes of morbidity and mortality posttransplant
• By identifying ‘at risk’ patients and modifying the risk
factors for poor graft survival, we could achieve better
outcomes for our patients in the long term
S34 Transplantation ■ February 2017 ■ Volume 101 ■ Number 2S www.transplantjournal.com• New patient-orientated technologies could enhance pa-
tient engagement, communication and treatment moni-
toring, and potentially translate into improvements in
long-term outcomesConclusions
The field of transplantation is evolving, and early graft and
patient survival rates have been on the increase across indica-
tions. However, graft and patient survival beyond the first
year have shown a more modest improvement over the last
decades. By routine monitoring and modification of the risk
factors associated with poor graft and patient survival with
the immunosuppression regimens that we use, we can in-
tervene to improve long-term outcomes for our patients
posttransplant. Only by aggressively tackling these risk fac-
tors pretransplant and posttransplant will we help to achieve
better outcomes in the longer term for our patients.
With the advent of immunosuppressive therapies, including
tacrolimus, we witnessed a revolution in the treatment of trans-
plant patients. However, advancement in transplantation
should not stop there; new advances in our understanding of
the field, innovative technology, novel therapeutics and changes
in the way research is conducted—using registries as well as
RCTs—will provide insights into how we can move forward
and further enhance the outlook for patients in need of trans-
plantation. Future technologies in areas such as organ engineer-
ing also provide uswith the potential to decrease our reliance on
life-long immunosuppression and increase the number of or-
gans available for transplantation. As we enter this new era,
wemust harness the information we have generated, reevaluate
how we treat patients and ensure that necessary changes are
rapidly incorporated into routine clinical practice.
More specifically, as we move toward a more personalized
approach to transplantation and redefine what “best prac-
tice” treatment looks like, our ability to integrate all available
and multidimensional data, including phenotypic, histopath-
ologic, transcriptomic and immunologic information, will
prove critical in identifying appropriate treatment approaches
for different patients. Only with this concerted effort can we
continue to make a difference to our patients’ lives.• As we enter the era of personalized and digitalized medi-
cine, wemust harness the informationwe have generated,
reevaluate how we treat patients and ensure that ne-
cessary changes are rapidly incorporated into routine
clinical practice
• Advances in our understanding of the field, innovative
technology, novel therapeutics and changes in the way re-
search is conducted—using registries as well as RCTs—
will provide insights into how we can move forward
and further enhance the outlook for patients in need
of transplantation
• By routine monitoring and modification of the risk fac-
tors associated with poor graft and patient survival
with the immunosuppression regimens that we use,
we can intervene to improve long-term outcomes for
our patients posttransplantACKNOWLEDGMENTS
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CORRECTION NOTICE
This online version of the Supplement to Transplantation
(Advancing Transplantation: New Questions, New Possibili-
ties in Kidney and Liver Transplantation by Wadström et al),
published in February 2017, has been revised from the original
published version. The Astellas job code and date of prepara-
tion have been updated from ‘ADV/16/0009/EU(1)’ and ‘Jan-
uary 2017’, respectively, to ‘ADV/16/0009/EU(2)’ and ‘March
2017’, on the front cover and page S1. The ‘Prescribing infor-
mation and adverse event reporting information’ on pages
S40–S41 has been replaced. Key changes are as follows: The
wording on pages S40–S41 has been updated for sections:
‘Posology and Administration’, ‘Prophylaxis of transplant
rejection’, ‘Therapeutic drug monitoring’, ‘Warnings and
Precautions’, ‘Interactions’, ‘Pregnancy and lactation’, and
‘Undesirable effects’. The following text has been added on
page S40: ‘Increased doses of tacrolimus, supplemental cortico-
steroid therapy and introduction of short courses of mono-/
polyclonal antibodies have all been used. If signs of toxicity
are noted the dose may need to reduced. For conversion to
PROGRAF, treatment should begin with the initial oral dose
recommended for primary immunosuppression’, and ‘Dose ad-
justments in specific populations: see SPC.’ The following text
has been added onpage S41: ‘MANumber: PROGRAF:Country
specific. ADVAGRAF: EU/1/07/387/001-26’ and ‘ADVAGRAF
andPROGRAFare registered trademarks.ADV/11/0030/EUc(4)’.
The date of revision for the ‘Prescribing information and ad-
verse event reporting information’ on page S41 has been changed
from ‘January 2017’ to ‘November 2015’. The address on page
S40 for obtaining additional information has been changed from
‘Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey, KT16
0RS’ to ‘Astellas Pharma Europe Ltd, 2000 Hillswood Drive,
Chertsey, Surrey, KT16 0RS, UK’.
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